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Abstract
The aim of these studies was to improve laboratory methods for the detection of virus- 
specific antibody to mumps and rubella. The presence of virus-specific antibody is 
indicative of immunity to disease so simple and effective antibody detection allows for the 
planning and monitoring of immunisation programmes.
In facilitating antibody surveillance, oral fluid has advantages as a sample compared 
with blood. It is simple, safe and cheap to collect and being non-invasive encourages 
subject recruitment. In this study, an 'IgG' antibody capture enzyme-linked 
immunosorbent assay (GACELISA) was developed and evaluated for the detection of 
mump-specific IgG in oral fluid. Compared to an indirect commercial ELISA for the 
detection of mumps-specific IgG in serum, the oral fluid GACELISA was 100% sensitive 
and specific. The GACELISA should therefore be useful for future antibody prevalence 
studies.
The limitation of oral fluid samples compared with blood are that they contain lower 
antibody concentrations. Immuno-polymerase chain reaction (I-PCR) is an ultrasensitive 
method and in this study was adapted to detect antibodies to mumps virus. Though the 
method was shown to be feasible for antibody detection and quantification, its sensitivity 
and specificity did not exceed that of a conventional ELISA. Sensitivity was limited by 
non-specific binding of human IgG to the solid phase. It is necessary to further develop 
reagents and assay formats to fully exploit the potential of quantitative I-PCR, so that 
potential improvements in the sensitivity of viral-specific IgG detection can be realised.
Increasingly, recombinant antigens are being employed in ELISAs as cell culture 
antigens are difficult and expensive to produce, and are potentially infectious. In this study, 
the PinPoint  Xa-1 T-Vector system was used to produce recombinant rubella virus (RV) 
El fusion proteins in Escherichia coli. Their antigenicity was assessed by Western blotting 
and ELISA. One of these antigens may be a suitable reagent for immunity studies as it 
reacted with RV El-specific monoclonal antibodies (MAb's) and a high percentage (80%) 
of RV antibody positive sera.
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1.1 Mumps
1.1.1 History
Mumps was first described in the fifth century B.C. by Hippocrates (in Book 1 of his 
Book of Epidemics}. He noted the characteristic swelling of the salivary glands (parotitis) 
and the common complication of painful swelling in one or both testes (orchitis). The 
origin of the word mumps is unclear but may derive from the old English verb meaning 
"grimace, grin or mumble" (cited Carbone and Wolinsky, 2001). In 1790, the physician 
Hamilton was the first to describe infection of the central nervous system (CNS) in some 
cases of mumps. In 1934, Johnson and Goodpasture showed that the disease could be 
transmitted from infected patients to monkeys. They also demonstrated the filtrable nature 
of the causative agent. The virus was first isolated and propagated in embryonated eggs in 
1945 by Habel, and in cell culture in 1955 by Henle and Deinhardt. This led to the 
development of live attenuated vaccines that have been used to control mumps (Buynak 
andHilleman, 1966).
1.1.2 Mumps virus
Mumps virus (MV) is a member of the genus Rubulavirus in the family 
Paramyxoviridae (Rima et al., 1995). The virion has an irregular spherical shape, with a 
diameter ranging from 90 to 300 nm and averaging approximately 200 nm. It consists of 
an internal ribonucleoprotein core (nucleocapsid) surrounded by a lipid bilayer membrane 
(Figure 1.1 a). The nucleocapsid (Figure Lib) displays the characteristic herringbone 
pattern of Paramyxoviridae and contains the ribonucleic acid (RNA) genome covered with 
the nucleocapsid-associated protein (NP), the phosphoprotein (P) and the large protein (L) 
(Orvell, 1978). The lipid membrane is derived from the host cell. Embedded within this 
membrane is the matrix protein (M), which interacts with the NP protein and the viral 
glycoproteins, haemagglutinin-neuraminidase (HN) and fusion (F) protein (Jensik and 
Silver, 1976; Orvell, 1978). Spikes of 12 - 15 nm in length protrude from the membrane 
and these contain the viral glycoproteins in homo- or hetero oligomeric complexes.
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Figure 1.1 Electron microscopy of Mumps virus (Magnification x 200, 000).
(a) Mumps virion studded with fine surface projections that represent the viral glycoprotein 
spikes. The membrane of the virion has partially broken allowing the escape of the 
nucleocapsid. Bar = 1 OOnm.
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(b) Mumps nucleocapsid showing the typical herringbone pattern. Bar = lOOnm 
(Magnification x 200,000).
Courtesy of Dr Hazel Appleton (Enteric, Respiratory and Neurological Virus Laboratory, 
Central Public Health Laboratory, Colindale, London).
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The RNA genome is an unsegmented, single stranded macromolecule of negative
polarity that contains 15,384 nucleotides. It encodes seven genes, the sequence of which
are known (Waxham et al, 1987; Waxham et al, 1988; Elango et al, 1989; Elliott et al.,
1989; Kovamees et al., 1989; Yamada et al., 1989). The order of the genes is: 3'-NP-P-M-
F-SH-HN-L-5' (Elango et al., 1988). As well as the six structural proteins mentioned
above the virus encodes a small hydrophobic (SH) protein (Elango et al., 1989; Elliott et
al., 1989) and induces the synthesis of the nonstructural (NS) proteins, NS2 and NS1, from
transcripts of the P gene (Takeuchi et al, 1988; Elliott et al., 1990; Paterson and Lamb,
1990). Many workers have contributed to our understanding of the structural polypeptides
of MV (Jensik and Silver, 1976; Huppertz et al., 1911 \ Orvell, 1978; Merz and Wolinsky,
1981; Naruse et al., 1981; Herrler and Compans, 1982; Server et al., 1982; Merz et al.,
1983), the findings of which are summarised in Table 1.1.
Table 1.1 Mumps virus proteins and their properties
Protein
Nucleocapsid- 
associated protein
Phosphoprotein
Matrix
Fusion
Small hydrophobic
Haemagglutinin- 
neuraminidase
Large
Molecular mass in 
SDS-PAGE (kDa)
68-73
45-47
39-42
65-74
74-80
180-200
Biologic activity
Major nucleocapsid-associated protein; protects 
genome from cellular ribonucleases
Phosphorylated protein associated with the 
nucleocapsid; forms part of the transcriptase complex
Membrane-associated protein; involved in 
nucleocapsid alignment
Surface glycoprotein with fusion activity; mature 
form is a disulphide-linked complex of F\ (58-61 kd) 
and F2 (10-16 kd)
Hydrophobic membrane-associated protein
Surface glycoprotein with haemagglutinin and 
neuraminidase activity; disulphide-linked oligomer in
native state
Nucleocapsid-associated protein, contributes to 
RNA-dependent RNA-polymerase
Adapted from Carbone and Wolinsky (2001).
SDS-PAGE, sodium dodecyl sulphate-polyacrylamide gel electrophoresis
kDa, kilodalton
K)
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1.1.3 Epidemiology
Mumps is mainly a childhood disease that has been reported worldwide. Before 
widespread immunisation, immunity to mumps was mostly acquired between the ages of 
five and nine years, and the prevalence of immunity was higher in densely populated urban 
areas compared with rural communities (Bennett et al., 1975; Anderson et al., 1987). In 
the Northern Hemisphere most cases occurred in the late winter and early spring months. 
The clustering of cases presumably reflected increased contact rates among susceptible
9
children attending school. Outbreaks of mumps were common among military personnel, 
where the potential for transmission to susceptible individuals was high due to 
overcrowding (Brooks, 1918).
MV needs a population of about 200,000 people to sustain it. The attack rate in virgin 
populations (reproduction number [number of secondary cases arising from a typical 
primary case] R = 5) suggests the virus is highly contagious, similar to influenza and 
rubella but less than measles (R = 16 - 450) and chickenpox. The infectious period is 
considered to be from three days before to approximately the fourth day of active disease 
(Brunell et al., 1968). While persons with asymptomatic or nonclinical infection can 
transmit the virus, no carrier state is known to exist.
The incubation period of infection with MV is usually 16 to 18 days, but symptoms may 
occur as early as 14 or as late as 21 days after exposure (Reed et al., 1967). Placental 
transfer of mumps antibody does occur, and probably provides protection in the early 
months of life. The major morbidity from mumps primarily results from complications of 
meningitis, encephalitis and orchitis. In the prevaccine era, mumps was the commonest 
identified cause of viral meningitis in children in England and Wales; there were 
approximately 1,200 hospital admissions a year associated with the disease (Anon, 1990a).
Humans are the only known natural hosts for the virus, although animal models have 
been described, including, mice (Tsurudome et al., 1987), rats (Rubin et al., 1998) and 
monkeys (Rubin et al., 1999). Only one serotype of MV has been identified but the virus 
cross-reacts serologically with other members of the Paramyxovirdae family, particularly 
the human parainfluenza viruses (Ito et al., 1987).
In industrialised areas of the world (e.g. the UK, USA and Scandinavia) mumps has 
been brought under control by the use of a safe and effective vaccine. Figure 1.2 shows the 
dramatic fall in the number of clinically diagnosed mumps cases reported to the Royal 
College of General Practitioners (RCGP) and the number of laboratory reports received by
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the Communicable Disease Surveillance Centre (CDSC) following the introduction of the 
measles, mumps and rubella (MMR) vaccine in the UK.
Figure 1.2 Mumps incidence (RCGP) and number of confirmed cases reported to 
CDSC from 1968 to 1996.
b "a
2 £
55 oo °
.o a,
« O
 GP consultation rates per 100,000 population
  Laboratory reports
MMR vaccine introduced
Year
Sources: data for 1968-1981 (Galbraith et al., 1984); data for 1982 - 1996 CDSC, 
Colindale, UK.
Despite high uptake rates of vaccine, outbreaks are still reported, sometimes due to 
importations from areas where the virus is endemic. Cases in vaccinated people are 
thought to result from both primary (failure to seroconvert) and secondary (loss of 
antibody) vaccine failures (Briss et al., 1994). Fortunately, vaccine failure is uncommon in 
individuals who receive two doses of vaccine (Hersh et al., 1991); the policy that has been 
instituted in most industrialised countries. Factors known to adversely affect vaccine 
"take" include: pre-existing antibodies, either of maternal or passively transferred origin; 
the presence of interferon due to ongoing viral infection at the time of vaccination; and loss 
of vaccine potency due to improper handling or cold storage (Gluck, 1991).
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1.1.4 Pathogenesis and clinical features
MV is transmitted by direct contact with saliva or droplets from the saliva of an infected 
person. During the incubation period the virus replicates in the nasopharynx, spreads to the 
draining lymph nodes and then disseminates to multiple organs via the bloodstream.
The severity of mumps infection is very variable. Approximately one third of all 
infections occur without producing noticeable symptoms, particularly in children (Philip et 
al., 1959; Levitt et al., 1970a). The prodromal symptoms are non-specific and include low- 
grade fever, headache, malaise, myalgia and anorexia. The most common manifestation of 
the disease is salivary gland swelling, particularly the parotid glands, which may be 
unilateral or bilateral. Gland enlargement tends to occur within the first two days and may 
be present for a week or more.
Various organs can be infected during mumps infection. CNS involvement is common, 
occurring asymptomatically in 40 - 60 % of cases (Bang and Bang, 1943; Holden, 1946; 
Levitt et al., 1970b). Symptomatic meningitis occurs in up to 15% of cases and usually 
resolves without sequelae in three to ten days. Encephalitis is reported to occur in 
approximately 0.5% of cases (Bennet et al., 1975). Orchids (inflammation of the testes) 
occurs in 20 to 35% of males, especially after puberty, (Philip et al., 1959; Reed et al., 
1967) and may lead to testicular atrophy but sterility is rare (Shulman et al., 1992). In 
females, oophritis (inflammation of the ovaries) may occur but is much less common (5%) 
than orchids in males (Reed et al., 1967). It is accompanied by pain and tenderness in the 
abdomen and may mimic appendicitis. There is no relationship to impaired fertility. 
About 15% of females also complain of mastitis (breast swelling and tenderness) (Philip et 
al., 1959). Other organs that may be clinically involved during mumps infection include, 
the eyes, heart, kidneys, pancreas, prostate, liver, spleen, thyroid, lungs, bone marrow and 
joints. All organs are generally affected after parotitis, but their involvement may be 
present before, during or even in the absence of parotids.
1.1.3 Immune response
The host immune response to MV infection consists of cell-mediated and humoral 
responses. The relative importance of these responses for the clearance of MV from the 
infected host is unclear. Virus-specific IgM responses can be demonstrated early in the 
infection and usually wane within two to six months (Bjorvatn, 1974; Ukkonen et al., 
1981). The detection of viral-specific IgM antibody is the most sensitive serological 
indicator of acute or very recent infection. Virus-specific IgG responses reach peak levels
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about the third week of clinical disease and are thought to persist indefinitely (Ukkonen et 
al, 1981). The major IgG response is composed of the IgGl subclass, with a minor 
contribution from IgG3 (Sarnesto et al, 1985a). Virus-specific secretory IgA can be 
detected five days after disease onset (Chiba et al, 1973) and most likely terminates viral 
excretion in saliva.
Both cytotoxic T cells and lymphoproliferative responses have been detected after MV 
infection. Kreth et al. (1982) demonstrated the presence of cytotoxic T cells reactive with 
MV in the blood and the CSF of patients with mumps meningitis. Donen (1979) using the 
blast transformation test detected in vitro lymphoproliferative responses to MV antigens in 
seropositive individuals.
Re-infection has been reported but is uncommon. Symptomatic reinfection may reflect 
waning vaccine induced immunity (Briss et al, 1994) or patients may be infected with a 
different strain of virus. Nojd et al (2001) described a chronic case of mumps where 
despite having a good neutralisation titre against genotype D, the patient was not protected 
against infection with genotype A. Alternatively, putative symptomatic reinfection in 
individuals with pre-existent antibody may reflect the lack of specificity of mumps tests 
due to known cross-reactivities of antibodies to other paramyxoviruses with MV antigens 
(Meurman et al, 1982; Orvell et al, 1986).
1.1.6 Diagnosis
The clinical diagnosis of mumps is based on presenting symptoms, particularly parotitis. 
Laboratory confirmation is often sought, which may involve isolating virus; detecting viral 
genome by reverse transcriptase polymerase chain reaction (RT-PCR); demonstrating a 
diagnostic rise in specific IgG antibodies; or detecting specific IgM antibodies.
Virus is most often isolated from respiratory secretions or urine. In patients with 
meningitis, virus can be isolated from the CSF. A variety of primary and continuous cell 
lines may be used for virus isolation, including primary monkey kidney cells, human 
embryonic kidney cells, HeLa cells, HEp-2 cells and B95a cells (Carbone and Wolinsky, 
2001; Knowles and Cohen, 2001). However, not all mumps strains produce cytopathic 
effects (CPEs) in vitro so haemadsorption using guinea-pig red blood cells (RBCs) and/or 
immunofluorescence may be necessary to confirm the presence of mumps. 
Haemadsorption occurs because the infection of cells in culture results in the expression of 
viral proteins on the cell surface that bind to erythrocyte membranes. Immunofluorescence 
detects mumps antigens by staining infected cells with virus-specific monoclonal antibody 
(MAb) labelled with a fluorescent tag such as fluorescein isothiocyanate (FITC). Virus
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isolation is advantageous as it provides an isolate of viable virus that can be further 
characterised and stored for future studies. However, as a diagnostic method it is slow and 
expensive; it requires specialised facilities and expertise.
RT-PCR can be used to detect virus isolated in cell culture or directly from clinical 
specimens (Boriskin Yu et al., 1993). Sequencing of the amplified fragments can provide 
useful epidemiological data and virus strain identification. The SH gene has been shown to 
be highly variable between strains and comparison of the nucleotide sequences of this gene 
from mumps strains collected worldwide has shown the existence often genotypes, namely 
A - J (Afzal et al, 1997; Wu et al., 1998; Jin et al., 1999; Kirn et al., 2000; Tecle et al., 
2001).
A wide range of assays are available to demonstrate a diagnostic (four-fold) rise in 
antibodies in serum taken at the onset of clinical disease (acute-phase) and 2 to 3 weeks 
later (convalescent-phase). These include plaque reduction neutralisation (PRN), 
haemagglutination inhibition (HI), haemolysis-in-gel (HIG), complement fixation (CF), 
and ELISA (Grillner and Blomberg, 1976; Freeman and Hambling, 1980). PRN, HI, HIG 
and CF are functional assays as they measure a biological function of the virus-specific 
antibody. PRN measures the capacity of mumps antibody in serum to block the infection 
of cells in culture. HI is based on the ability of MV to haemagglutinate RBCs. If specific 
antibodies are incubated with MV before the addition of RBCs, they will prevent 
haemagglutination. HIG, like the HI assay, relies on the presence of antibody to the MV 
haemagglutanin. Antibody detection is based on complement-mediated lysis of MV 
antigen-sensitised RBCs suspended in an agarose gel. CF measures the ability of mumps 
antibodies to fix complement, preventing the complement from lysing indicator RBCs. 
Two different antigens are routinely used in CF tests: the viral (V) and the soluble (S) 
which correspond to the HN and NP of mumps respectively (Jensik and Silver, 1976).
Although the techniques described above have been widely used in the past, they are 
increasingly being replaced by the ELISA. ELISA is a relatively sensitive, specific, rapid, 
and cost effective method that can be automated. Also, it allows for isotype determination 
(i.e. IgG, IgM or IgA). Various ELISA formats have been described including the indirect, 
competitive, sandwich and antibody capture. They all rely on the binding of virus-specific 
antibodies to viral antigens. ELISA for virus-specific IgM antibodies is important as it 
allows a specific diagnosis to be made on the basis of a single serum specimen collected 
during the acute-phase of illness.
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I.1.7 Control
In developing countries mumps is not considered a major public health problem. In 
these countries, children usually are immune by the time they enter school because of 
subclinical infections acquired early in life. By contrast, extensive cost-benefit analysis 
favours the routine vaccination of children against mumps in affluent developed nations 
(Koplan and Preblud, 1982; Galazka et al, 1999).
(i) Mumps vaccines
The first mumps vaccine developed was killed vaccine, which was licensed for use in 
1950. However it produced only short-lived immunity and required periodic booster 
injections, so when the more effective live attenuated vaccines were developed, killed 
vaccine was no longer used (Plotkin and Wharton, 1999).
Several different strains of live attenuated MV have been developed for vaccine use, 
including Jeryl Lynn, Urabe, and Rubini. The Jeryl Lynn was the first vaccine strain to be 
developed (by Merck Sharpe and Dohme) and was attenuated by serial passage in 
embryonated hens' eggs and chick embryo cell cultures (Buynak and Hilleman, 1966). 
Over 100 million doses of vaccine manufactured with this strain have been administered 
worldwide since it was first licenced for use in 1967. More recently, the Jeryl Lynn 
vaccine has been shown to contain a mixture of at least two closely related strains, JL5 and 
JL2, at a ratio of five to one respectively (Afzal et at., 1993). A new vaccine (RIT 4385) 
derived from the JL5 component has recently been licenced in Europe (cited Carbone and 
Wolinsky,2001)
The Urabe vaccine was developed in Japan in 1982 by the Biken Institute and has been 
used in Japan, North America and Europe. However, it has been removed from many 
markets, as its use has been associated with an increased incidence of meningitis (Hockin 
and Furesz, 1988; Furesz and Contreras, 1990; Sugiura and Yamada, 1991). For example, 
in the UK, Miller et al (1993) reported 23 cases of aseptic meningitis (estimated at 1 in
II,000 doses) associated with Urabe vaccine compared with no cases after vaccination with 
the Jeryl Lynn vaccine. These findings led to the withdrawal of mumps vaccine containing 
the Urabe strain from immunisation schedules in the UK. More recently, Brown et al. 
(1996) showed that the Urabe vaccine was a mixture of viruses differing at amino acid 335 
of the HN gene, possessing either wild type Lys335 or mutant Glu335, while clinical 
isolates were homogeneous and possessed the wild type Lys335. They suggested that post- 
vaccine meningitis was associated with virus containing the wild type Lys335.
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Comparative immunity studies have shown the Urabe vaccine strain is more efficacious 
than the Jeryl Lynn vaccine strain. Poppw-Kraupp et al. (1986) measured the antibody 
responses of 400 children by ELISA and showed 96.9% of children seroconverted when 
they received the Urabe vaccine compared to 90% of the Jeryl Lynn vaccine recipients. 
Miller et al. (1995) showed children given vaccine containing the Urabe vaccine strain 
were less likely to be antibody negative than those given the Jeryl Lynn vaccine strain. 
Boulianne et al. (1995) showed the prevalence of children without detectable antibody 
levels were 14.9 and 7% for the Jeryl Lynn and Urabe vaccine strains respectively. These 
results are consistent with the idea that the Urabe vaccine strain disseminates more widely 
in the host than the Jeryl Lynn vaccine strain.
The Rubini vaccine was developed in Switzerland in 1986 and is the only vaccine 
produced on human diploid cells. Although it was initially shown to be highly 
immunogenic, the clinical efficacy of the Rubini strain has been questioned following 
outbreaks in Switzerland (Schlegel et al., 1999), Portugal (Afzal et al, 1997) and 
Singapore (Goh, 1999). As a result of all the above findings, in the USA, Canada, the UK 
and several European countries, mumps vaccines contain the Jeryl Lynn vaccine strain.
Mumps vaccines have been produced as monovalent, bivalent measles-mumps and 
trivalent measles-mumps-rubella (MMR) preparations as health authorities recommend all 
three vaccines to be given to the same age group. In clinical studies to assess the efficacy 
of the trivalent vaccine, it was found that simultaneous administration of all three 
components at the same dosage levels [1000 Tissue culture infective dose (TCIDso) = 
highest dilution of virus suspension which produces a CPE in 50% of the cell cultures 
inoculated] as for the monovalent preparations resulted in a substantial reduced 
seroconversion rate for mumps, but not for measles or rubella. To address this, the number 
of viable mumps viruses in the trivalent preparation was increased to 5000 TCID50 (Andre 
and Peetermans, 1986; Berger et al., 1988). Despite this, the results of immunity studies 
suggest the mumps strain is still the weakest immunogenic part of the combined vaccine 
(Christenson and Bottiger, 1991; Gay et al., 1997). In the UK there are two licensed MMR 
vaccines: Priorix (Smithkline Beecham) and MMR II (Aventis Pasteur). Both contain the 
Jeryl Lynn strain of mumps. There is no single antigen mumps vaccine licensed for use in 
the UK.
Post vaccination antibody titres develop more slowly and are lower than those following 
natural infection. Weibel et al. ( 1967) found the mean neutralisation antibody titres were 
1:9 and 1:6 following vaccination and natural disease respectively. It is unclear whether a
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single dose of properly administered vaccine provides life-long immunity. Neutralising 
antibody has been shown to persist for more than 19 years (Plotkin and Wharton, 1999) but 
these subjects may have been exposed to mumps during this time resulting in a boosting of 
their antibody levels.
(ii) Adverse reactions
Mumps vaccines, alone or in combination, are generally considered to be safe. Adverse 
reactions are uncommon and mild. The most common adverse reactions are transient fever 
and mild parotitis and orchids.
(iii) Vaccination programmes
In the UK, immunisation against mumps was first introduced in October 1988 as one 
component of the MMR vaccine offered to children aged 12 to 15 months with the aim of 
eliminating the disease. In addition, all preschool children were offered the vaccine in a 
three-year catch up programme; some districts extended the programme to children aged 5 
to 10 years. In the first two years of the vaccine programme, there was a 79% reduction in 
notified cases in England and Wales and the vaccination coverage exceeded 90% in some 
areas (Jones et al., 1991). Despite this, Miller et al. (1995) showed that between 15 and 
19% of children vaccinated at age 12 to 18 months were seronegative 4 years after 
vaccination. Concerns raised by this and other studies led to the adoption of a two-dose 
regimen in October 1996, where the first dose is administered at 12 to 15 months of age, 
and the second dose is given before school entry at 4 to 5 years of age. Other industrialised 
countries have adopted a similar immunisation policy, although some administer the 
second dose at 11 to 13 years of age (Johnson et al., 1996). In developing countries with 
no previous vaccination programme, the World Health Organsiation (WHO) recommends 
that the introduction of mumps vaccine be considered only if the country is in the process 
of establishing adequate programmes for the elimination of measles and rubella.
1.1.8 Mumps outbreaks
Despite the overall reduction in the incidence of mumps, outbreaks of mumps have been 
reported in the UK (van den Bosch et al., 2000; Reaney et al., 2001) and elsewhere (Briss 
et al, 1994; Strohle et al., 1997). Between July 1998 and April 1999, 144 cases of mumps 
were notified in North London; all but two were members of a religious community (van 
den Bosch et al., 2000). The median age of cases was 10 years and approximately half of
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both the clinical and laboratory confirmed cases had received one dose of MMR vaccine, 
while only three cases had received two doses. The immunisation coverage for the first 
and second doses of MMR vaccine at the time was between 67% and 86% in this particular 
community. Around the same time as this outbreak there were outbreaks in similar 
religious groups in Israel, New York and Russia. Members of these communities often 
travel between these centres but do not mix much outside there own community. This may 
explain why the outbreak spread to similar communities in different countries but not 
outside the communities locally.
An outbreak of mumps was also been recently reported in Northern Ireland (Reaney et 
al., 2001). Between 1 st November 1999 and 31 st August 2000, 729 cases of mumps were 
notified. Of those who underwent confirmatory laboratory testing, infection was found in 
77% (332/450). Three hundred and sixteen (95.2%) of these confirmed cases were in the 
age range 9 to 19, with a median of 10 years. One hundred and eighty-four (55.4%) 
confirmed cases had received one dose of MMR but only 3 (0.9%) confirmed cases had 
received 2 doses of MMR. Schools appeared to be the focus for the spread of infection, 
especially secondary schools where the children travelled longer distances to school, 
usually in crowded buses providing an opportunity for spread.
Detailed analysis suggested that these outbreaks were mainly a reflection of the pool of 
susceptible children, teenagers, and young adults who either missed or failed to respond to 
vaccine during the first years following the introduction of the one-dose policy. Using 
susceptibility data and mixture modelling, Gay et al. (1997) predicted that the proportion of 
children aged 11 to 15 years with no detectable antibody to mumps was expected to peak at 
19% in 1997, and suggested that this increase in susceptibility was unlikely to allow a large 
resurgence of mumps in the short term but school outbreaks would become more common. 
Their predictions were correct. The outbreaks question the efficacy of the mumps vaccine 
and clearly show that one dose of vaccine does not give adequate protection against 
mumps. Many young people received measles and rubella vaccine in a mass vaccination 
campaign in 1994 but no second dose of mumps vaccine. If mumps had been included in 
this vaccination campaign the outbreaks detailed above would have been prevented.
In recent years, uptake rates of MMR have fallen (Figure 1.3) following adverse 
publicity about the vaccine. This stemmed from the suggestion that measles and MMR live 
attenuated vaccines may cause juvenile Crohn's disease (JCD) and autism (Thompson et 
al., 1995; Wakefield et al., 1998; Wakefield et al., 1999). The proposed link initially 
emerged from epidemiological and case control studies that claimed a temporal relationship
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between the rising numbers of JCD cases and the introduction of live attenuated measles 
vaccine in the UK (Thompson et al., 1995; Wakefield et al., 1999). However, other reports 
suggested that the observed rise in the number of inflammatory bowel disease (IBD) cases 
started much earlier than the introduction of the measles vaccination campaign (Hermon- 
Taylor et al, 1995; Miller et al., 1998; Taylor et al., 1999). As well as the epidemiological 
evidence, the presence of measles virus in clinical tissues obtained from cases of JCD and 
ulcerative colitis has been reported (Wakefield et al., 1993). However the specificity of the 
techniques used to detect measles has been questioned. Further studies using more specific 
techniques (gene-specific RT-PCR and nested RT-PCR) were used by a number of 
independent groups however none were able to demonstrate the presence of measles virus 
genome in gut tissues taken from IBD cases (lizuka et al., 1995; Haga et al., 1996; Afzal et 
al, 1998a; Afzal et al, 1998b; Chadwick et al, 1998). Also, more recent serological and 
epidemiological studies show a lack of association between measles or MMR vaccines and 
the development of IBD and autism (Feeney et al, 1997; Peltola et al, 1998). As a result 
the government continues to recommend MMR.
Figure 1.3 Completed Primary Courses of MMR vaccine at Two Years of Age in 
England and Wales, 1992 - 2002.
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Source: Department of Health Statistics Division
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1.2 Rubella
1.2.1 History
For many centuries rubella was confused with measles and scarlet fever as it is 
characterised by a rash. It was first described in the mid 18th century by two German 
physicians, de Bergen and Orlow and was known by the German name Rotheln 
(Wesselhoeft, 1947); it was due to the early interest of the German physicians and its cause 
of a measles-like illness (albeit a milder form) that the disease subsequently became known 
as "german measles". The name rubella, derived from the Latin meaning "little red", was 
proposed by the English physician Henry Veale in 1866 as he found the original name 
"harsh and foreign to our ears".
In 1914, Hess proposed the viral aetiology of rubella based on his work with monkeys. 
Hiro and Tasaka (1938) confirmed the viral aetiology of the disease by transmission of 
rubella to susceptible children using filtered throat washings from acute cases (cited 
Forbes, 1969).
Until relatively recently, rubella was considered to be a mild illness. However, 
following a widespread epidemic of rubella infection in Australia in 1940, Norman 
M°Alister Gregg, an Australian ophthalmologist noted a striking increase in the number of 
infants with congenital cataracts (Gregg, 1941). He proposed that the cataracts and often 
associated cardiac defects were the result of maternal infection during pregnancy. 
Although at the time he was doubted, studies by other investigators supported his findings 
(Greenberg et al., 1957; Lundstrom, 1962; Pitt and Keir, 1965) and further revealed a wide 
range of abnormalities associated with intra-uterine rubella infection.
The virus was first isolated in cell culture independently by Weller and Neva (1962) and 
by Parkman, Buescher and Artenstein (1962). This led to the development and subsequent 
licencing of live, attenuated virus vaccines in the US in 1969 and in Britain in 1970.
1.2.2 Rubella virus
Rubella virus (RV) is the only member of the genus Rubivirus in the family 
Togaviridae. The RV virion contains an RNA genome enclosed in an icosahedral capsid, 
which is surrounded by a lipid bilayer. The nucleotide sequence and organisation of the 
RV genome have been resolved (Dominguez et a/., 1990; Frey, 1994). It consists of a 
single stranded 40S RNA of positive polarity (about 11,000 bp in length) which contains 
two long open reading frames (ORFs): a 5' ORF that encodes two non-structural proteins
1. General Introduction 34
(pi50 and p90) that function primarily in viral replication, and a 3' ORF that encodes the 
virion structural proteins (C, E2 and El) (Oker-Blom et al., 1984; Marr et al., 1994). In 
RV infected cells, the 5' ORF is translated from the genomic RNA while the 3' ORF is 
translated from a 24S subgenomic RNA. The translation of the 24S subgenomic RNA 
produces a 110 kDa precursor polyprotein (pi 10) that is proteolytically processed to yield 
the structural proteins in the order: NH2-C-E2-E1-COOH (Kalkkinen et al, 1984; Oker- 
Blom, 1984). The capsid protein C (33 kDa) is a nonglycosylated protein that is associated 
with the 40S genomic RNA (Oker Blom et al 1983; Liu et al, 1996). El (58 kDa) and E2 
(42 - 47 kDa) are envelope glycoproteins that form heterodimeric complexes (Baron and 
Forsell, 1991) and are found on the virion surface as viral spikes. The region between 
amino acids 81 and 109 of the El glycoprotein is thought to be involved in interaction with 
the E2 glycoprotein (Yang et al, 1998). El consists of 481 amino acids and has three 
potential N-linked glycosylation sites (asn-X-Ser/Thr) (Hobman et al, 1991). E2 is smaller 
than El, consisting of 282 amino acids and the number of N-linked glycosylation sites 
appears to vary depending on the strain. Oker-Blom et al (1983) showed the E2 
glycoprotein migrates as two different species in SDS-PAGE, designated E2a (47 kDa) and 
E2b (42 kDa). The heterogeneity is thought to be due to post-translational modifications of 
a single gene product as tryptic maps of E2a and E2b were identical and intrinsic labelling 
experiments with [3H] mannose showed that mannose was more efficiently incorporated 
into E2b than into E2a. El has been suggested to be the immunodominant glycoprotein as 
it bears the majority of MAb-defined erythrocyte binding and neutralising epitopes (Ho- 
Terry et al, 1984; Trudel et al, 1985; Umino et al, 1985; Waxham and Wolinsky, 1985; 
Green and Dorsett, 1986; Gerna et al, 1987). Although a neutralising epitope has been 
identified on the E2 glycoprotein (Green and Dorsett, 1986) it has been less well 
characterised. It is thought E2 is largely based beneath El in the virus particle and is 
inaccessible to the action of enzymes (i.e. glycosidase) and the immune response.
1.2.3 Epidemiology
Rubella has a worldwide distribution (Cockburn, 1969). In temperate climates, prior to 
rubella vaccination, immunity to rubella was mostly acquired between the ages of five and 
nine years, with the disease being less common among pre-school aged children (Kono et 
al, 1985). Epidemics of rubella usually occurred in the spring months at intervals of 
three to nine years, depending on geographic location (Assaad and Ljungars-Esteves, 
1985). Infection rates during the course of an epidemic were highest among closely 
housed susceptible individuals, such as student populations and military establishments.
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In developing countries without a national rubella vaccination policy, infection is 
common in both pre-school aged children and in five to nine year olds (Gomwalk and 
Ahmad, 1989; Cutts et al., 1997). Despite this a substantial proportion of women of 
childbearing age are susceptible (10 - 25%), and epidemiological studies conducted in 
South America (De Azevedo Neto et al, 1994) and India (Kishore et al., 1990; Eckstein et 
al., 1996) suggest that the burden of congenitally acquired rubella may be considerable; 1 
to 2 per 1000 live births (Cutts et al., 1997).
Rubella is a human disease and has no known animal reservoir. The incubation period 
ranges from 12 to 23 days and the period of infectiousness in acquired rubella is believed to 
be seven days before the rash to about five days afterwards; patients who do not develop a 
rash are also infectious (Davis et al, 1971). Infants with congenital infection may shed RV 
for an extended period but no true carrier state has been described
In developed countries that have achieved high uptake rates for rubella vaccine, 
acquired and congenital rubella is now uncommon. Unlike for mumps, outbreaks of 
rubella have not been reported recently in the UK.
1.2.4 Pathogenesis and clinical features
Rubella virus is transmitted by direct contact or droplet spread from both acquired and 
congenital cases. The virus initially replicates in the nasopharynx and the upper respiratory 
tract, followed by spread to the regional lymph nodes. A viremia occurs five to seven days 
after exposure, with spread of the virus throughout the body. Transplacental infection of 
the foetus occurs during viremia, which causes destruction of foetal tissues.
Rubella infection in early childhood or adult life is usually mild, with 20 to 50% of 
cases passing as subclinical or unrecognised events (Green et al, 1965). Clinically 
apparent rubella is characterised by any combinations of symptoms that include 
maculopapular rash, enlarged lymph nodes, mild fever, and sore throat. The most common 
complication is transient joint involvement such as arthralgia and arthritis. Less frequent 
complications are encephalitis and thrombocytopenia. The course of the acquired infection 
and the accompanying immune response is shown in Figure 1.4.
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Figure 1.4 Schematic diagram representing the course of postnatally acquired 
rubella infection.
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Adapted from Chantler et al. (2001).
The major risk of rubella virus is infection during early pregnancy (the first 12 weeks) 
resulting in virus passage across the placenta and replication in the foetus, causing severe 
birth defects, such as deafness, cataract, cardiac abnormalities, microcephaly and 
sometimes in foetal death. These congenital abnormalities are referred to as congenital 
rubella syndrome (CRS).
1.2.5 Immune response
Rubella-specific IgM response develops quickly after the onset of symptoms and 
persists for four to twelve weeks, although it can be detected for up to one year after both 
naturally acquired infection and rubella immunisation (Al-Nakib et al, 1975). The IgG 
response can be also detected early and is thought to persist for life. Sarnesto et al. (1985b) 
showed the IgG response is predominantly IgGl. O'Shea et al. (1985) demonstrated that 
serum IgA was detectable in 90% of vaccinees one year after vaccination but in only 45.5% 
of vaccinees 10-12 years after vaccination, while nasopharyngeal IgA was detectable for 
up to five years after vaccination with RA27/3 or natural infection. Rubella specific IgD 
and IgE antibodies increase rapidly after the onset of infection, remain at a high level for at 
least 2 months, and decline slightly by 6 months (Salonen et al., 1985).
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Most of the humoral response appears to be directed at the El glycoprotein with 
proportionally lesser amounts of the response directed at E2 and C (Katow and Sugiura, 
1985; Chaye et al, 1992b). Using a mouse model, Cusi et al (1995) showed that the El 
was essential for protection and that mice immunized with recombinant E2 and C proteins 
alone were not sufficient to protect the animals against RV infection. The avidity of IgG 
antibody to El matures during the two years following rubella infection (most pronounced 
in the first three months), but IgG anti-E2 and anti-C show minimal avidity maturation 
(Mauracher et al, 1992; Bottiger and Jensen, 1997; Hedman et al, 1989). IgG avidity 
development is reported to be slower in vaccinees than in patients with natural infection 
(Nedeljkovic et al, 2001).
A generalised immunosuppression occurs following natural and vaccine-related rubella 
(Mailer et al, 1978; Mailer and Soren, 1978; Buimovici-Klein and Cooper, 1979; Niwa 
and Kanoh, 1979). Niwa and Kanoh (1979) detected a decrease in total leucocytes, 
neutrophils and T cells, and a marked insensitivity to dinitrochlorobenzen and purified 
protein derivative in many patients. However, RV-specific cell-mediated immune 
responses develop and can be measured in vitro within one or two weeks of onset of 
clinical illness, and may persist for many years.
Reinfection can occur (Horstmann et al, 1970; Vesikari, 1972). Horstmann et al 1970 
reported asymptomatic reinfection in five of 149 recruits exposed to rubella during an 
epidemic. These individuals all had HI antibodies from previous natural infection. The 
risk of reinfection was greater in persons with low HI antibody titres. Reinfection during 
pregnancy resulting in viral spread to the foetus has been documented but is rare (Best et 
al, 1989; Weber et al, 1993).
1.2.6 Diagnosis
Clinical diagnosis of rubella is unreliable so laboratory confirmation is needed to 
confirm suspected cases. Accurate diagnosis is especially essential in pregnant women as 
termination is an accepted means of preventing congenital rubella. The methods used are 
similar to those used to confirm mumps infection.
Postnatally acquired rubella is usually diagnosed serologically by the detection of RV- 
specific IgM or a fourfold rise in specific IgG between acute and convalescent specimens 
by ELISA. PRN, HI, HIG have also been employed to detect RV-specific IgG but these 
are now used infrequently as they are time consuming and automated methods are not 
available. ELISA for the detection of RV-specific IgM is sensitive but may be 
compromised by cross-reactivity with other viruses, such as parvovirus B19 or Epstein Barr
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virus (EBV), or by the presence of rheumatoid factor, which can lead to false positive 
results. More recently, tests for specific IgG avidity have been developed and used as an 
alternative or additional test for recent infection (Thomas and Morgan-Capner, 1988; 
Thomas and Morgan-Capner, 1991). This has been possible as the avidity of specific IgG 
from cases of primary infection is low compared with that from people with past infection 
or reinfection. Two approaches, the shift value and index methods have been described. 
The shift value method compares absorbances with and without a protein denaturant (e.g. 
diethylamine or urea) in the serum diluent over a range of serum dilutions and the 
difference between the dilution curves is measured. While the index method compares 
absorbance's at a single serum dilution, with and without denaturant in the wash fluid used 
after the antigen/serum incubation (Thomas and Morgan-Capner, 1991).
Virus isolation is rarely used to diagnose acquired rubella, as it is labour intensive and 
slow. However, it is sometimes of use for determining the duration of excretion in 
congenitally infected infants as they might transmit infection to susceptible contacts. RV 
can be isolated from nasopharyngeal secretions, faeces, urine, and the CSF of infants with 
CRS, as well as from cord blood or placental tissue of the mother at the time of birth. RV 
can be identified by the production of CPE in rabbit kidney (RK13) or Vero cells, by 
interference in primary vervet monkey kidney cells or by immunofluorescence for the 
detection of antigen in RK13, BHK21 or Vero cells (Banatvala and Best, 1998).
RT-PCR can be used to detect virus isolated in cell culture or directly from clinical 
specimens. Amplified fragments can be sequenced to confirm the correct RV genome 
fragment has been amplified and to provide useful epidemiological information.
1.2.7 Control
Rubella is a public health problem because primary infection in the first trimester of 
pregnancy gives rise to foetal damage. In some developing countries, due to large families 
and overcrowding most children experience a rubella infection, which is often subclinical, 
early in life. Therefore very few women of childbearing age are susceptible to infection, 
and CRS is too rare to warrant large-scale immunisation efforts. In other countries with 
moderate transmission rates (where rubella vaccine has not been introduced) a significant 
proportion of women of childbearing age are still susceptible to rubella and CRS is an 
important public health problem. In contrast, many industrialised countries have 
practically eliminated rubella through the widespread use of live attenuated vaccines.
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(i) Rubella vaccines
Several live attenuated RV strains have been used for the production of rubella vaccines,
including, Cendehill (grown in rabbit kidney cells), HPV-77 (grown in duck embryo cells)
and RA27/3 (propagated in human diploid fibroblast cells) (Plotkin, 1999). The vaccine
containing the RA27/3 strain is the most widely used as it is highly immunogenic and has a
low rate of side effects; it is attenuated in human cells and is therefore not subject to
possible side effects associated with vaccines grown in non-human cells (Plotkin et al,
1973). It is manufactured by Merck, Sharpe and Dohme and is available in monovalent,
bivalent (measles-rubella) or trivalent (MMR) vaccines. Antibody responses to rubella as
part of the triple vaccine are the same as those seen after rubella vaccination as a single
antigen and are produced in 95% of vaccine recipients older than 12 months of age (Weibel
et al., 1980). Although antibody titres are lower than those following natural infection,
protection is believed to endure for more than 12 years in most of those immunised
(Herrmann et al, 1982; O'Shea et al, 1984; Horstmann et al, 1985; O'Shea et al, 1988).
Reinfection has been reported in a small number of individuals following vaccination.
Cusi et al (1993) found subclinical reinfection (defined by a fourfold rise in preexisting
antibody titre) in about 10% of girls immunised 5 years previously with the RA27/3
vaccine after reexposure of the virus during an epidemic.
(ii) Adverse reactions
Adverse reactions to rubella vaccines include fever, lymphadenopathy, arthralgia and 
arthritis. Mostly these reactions are less severe than following natural infection. Tingle et 
al (1986) showed wild type rubella infection in adult populations is associated with a 
higher incidence, increased severity, and more prolonged duration of joint manifestations 
than is seen after RA 27/3 rubella immunisation. Joint manifestations appear to be age 
related, being uncommon in children of both sexes but occurring more frequently in 
postpubertal females.
(iii) Vaccination programmes
Several rubella vaccination policies have been developed in different countries with 
markedly varied initial results. In the USA and Finland a policy of universal childhood 
immunisation was introduced, supplemented by vaccine administration to susceptible 
postpubertal women. This policy resulted in a marked decrease in the incidence of
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postnatally acquired and congenially acquired rubella in these countries (Anon, 1990b). In 
contrast, in the UK and other European countries, a selective vaccination programme was 
adopted where teenage girls aged 11 to 14 years were immunised, allowing natural rubella 
to continue to circulate (Hinman, 1985; Tobin et al, 1985); this was due to concerns that 
vaccination would not provide long-lasting protection. However, after a rubella epidemic 
in the UK in 1986, the vaccination programme was augmented by offering rubella as a 
component of the MMR vaccine programme aimed at eliminating circulating rubella (Best 
et al., 1987). Other countries have also switched to universal vaccination of infants, 
supplemented with the vaccination of seronegative adult women (Sullivan et al., 1999).
Since the introduction of MMR in the UK, rubella and CRS has declined sharply and 
has remained at a low level. Table 1.2 shows the number of cases reported to the National 
Congenital Rubella Programme from 1983 to 2001.
Table 1.2 Cases reported to the National Congenital Rubella Programme
Year of birth
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
Congenital Rubella Syndrome
49
35
17
24
29
18
8
9
3
7
1
7
1
12
0
0
1
4
1
Source: CDSC, Colindale, London.
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Despite the fall in the number of rubella and CRS cases, serological surveillance studies 
showed that a high percentage (-15 - 20%) of young men were susceptible to rubella and 
that continuing outbreaks among young men posed a risk of transmission of rubella to 
pregnant women. This led to the inclusion of rubella in the national immunisation 
campaign carried out in 1994 in the UK, primarily to prevent an epidemic of measles, 
where all children aged 5 to 16 years were offered measles-rubella vaccine. Following the 
campaign, in children aged 5 to 10 years, the proportion without rubella antibody fell from 
17.5% to 3.0% (there was no difference in susceptibility between the sexes) and in 11 to 16 
year olds the proportion fell from 6.2% to 1% in females and 24.5% to 6.9% in males; the 
lower susceptibility in the females reflected the effect of the selective vaccination up to 
1994 (Miller et at., 1997). Following this it was agreed to discontinue vaccination of 
schoolgirls but to continue to ensure that susceptible pregnant women were vaccinated 
postpartum.
Due to the success of rubella vaccination in virtually eliminating CRS from the 
industrialised world, there has been a recent drive to eradicate rubella worldwide. The 
WHO now recommends the addition of rubella vaccine to the measles vaccine when it is 
already being administered.
1.3 Surveillance
Vaccination is one of the most successful and cost-effective disease prevention 
interventions in public health. The use of an effective vaccine enabled the global 
eradication of smallpox (Fenner, 1980) and has greatly reduced the incidence of many 
vaccine-preventable diseases in industrialised countries. The WHO Expanded Program on 
Immunisation, which was established in 1974, has extended these benefits to developing 
countries (Henderson, 1984).
Critical to the success of any immunisation programme is a comprehensive surveillance 
system that allows measurement of health impact, definition of target populations for 
vaccination, evaluation of the impact of the immunisation programme and detection of 
problems requiring alterations in immunisation strategy.
The CDSC in the UK and Centre for Disease Control (CDC) in the US carry out 
continual surveillance on a variety of infectious diseases, including mumps and rubella. 
The WHO performs a similar role but at an international level. At a national level 
surveillance information comes from a variety of sources, including health care providers, 
laboratories, hospital records and death certificates (Orenstein and Bernier, 1990).
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In England and Wales, data on disease incidence mostly relies on statutory notifications 
by doctors to the proper officer of the local authority, who is usually the Consultant for 
Communicable Disease Control (CCDC). The proper officer sends a weekly return to the 
Office of National Statistics (ONS). Statutory notifications are important to detect short- 
term trends in disease incidence and outbreaks of disease so that immediate action can be 
taken to prevent the spread of infection; mumps and rubella were made notifiable diseases 
in the UK in October 1988.
Recently, MMR disease surveillance was enhanced to provide more accurate data as it 
was demonstrated that the predictive value of clinical notifications declines with decreasing 
incidence of disease; Brown et al (1994) found only 85 of 236 (36%) clinically diagnosed 
cases of measles could be confirmed in the laboratory. Since 1994 the PHLS (now HP A) 
has offered confirmatory testing of clinical notifications. Oral fluid-testing kits have been 
distributed to CCDC's in all health authorities, so when a case is notified, a kit is sent to the 
reporting doctor requesting a sample of oral fluid. The sample is taken by the practice 
nurse, doctor, parent or patient themselves and posted in a reply-paid box to the Specialist 
and Reference Microbiology Division (SRMD) at Colindale, London. Samples are tested 
for virus specific IgM by antibody capture radioimmunoassays (Perry et al 1993) to 
confirm recent infection. Results are returned to the CCDC and the doctor. Confirmed 
cases are reported to the CDSC. In 2001, 63% (1774/2806) of the notified cases of 
clinically diagnosed mumps were tested for mumps-specific IgM antibody, and antibody 
was detected in 574 (32%).
As well as disease incidence, adverse events following vaccination, vaccine efficacy and 
coverage should be monitored in a comprehensive surveillance programme. For example, 
vaccination coverage is important to enable changes in uptake to be detected quickly. This 
can be achieved by monitoring vaccine distribution and by monitoring the doses of vaccine 
administered to children in target age groups. In England and Wales, CDSC carry out 
surveillance of childhood vaccination uptake. The programme is known as COVER 
(Cover of Vaccination Evaluated Rapidly) and was established to: improve vaccination 
cover by providing programme coordinators with timely comparative information; detect 
rapidly local and national changes in vaccination cover; encourage the development and 
dissemination of quarterly reporting within districts; and identifiy measures and remedies 
for poor performance (Begg et al., 1989).
Interpretation of surveillance data and summary statistics are disseminated regularly in a 
variety of ways, including local and national newsletters, the HPA website, letters from the
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Chief Medical Officer and journals, such as the Communicable Disease Report and the 
Mortality and Morbidity Weekly Report so that the medical community is made aware of 
trends in patterns of disease and action can be taken quickly and efficiently.
1.4 Serological surveillance
Another important component of any immunisation programme is serological 
surveillance, especially age stratified antibody prevalence studies. Since the presence of 
antibody can be used to indicate immunity (or exposure to vaccination or past infection), 
serological surveys can identify those age groups at risk of infection. This information, 
especially when combined with mixture modelling, is particularly useful for evaluating the 
need for and the planning of new vaccination programmes and supplementary measures. 
Identifying cohorts with low immunity enables vaccination strategy to be updated 
accordingly.
In the UK, a serological surveillance programme was introduced just before the 
introduction of MMR in 1988 and has been running every year since. Serum aliquots, 
residues remaining from microbiological or biochemical testing, are collected by 
participating PHLS and National Health Service laboratories and are sent to Preston PHL 
where they are tested for IgG antibodies to MMR. Results are then forwarded to CDSC 
where the information is entered into a central database and analysed.
The serological surveillance programme has directly influenced national vaccination 
policy. The first age-stratified survey was conducted in 1986/7 (Morgan-Capner et al., 
1988). The results showed that 60% of 1 - 2 year olds did not have measles antibody 
(despite the measles vaccination programme at that time) and over 80% did not have 
antibody to mumps or rubella, whereas 17%, 55% and 73% of children aged 3-4 years 
were suscceptible to MMR respectively. These findings suggested that vaccinating 
children early in life would be necessary to eliminate disease and was a central factor in the 
decision to offer MMR to infants 12 to 15 months old.
The decision to carry out the national measles and rubella (MR) immunisation campaign 
in 1994 was also based on the findings of the serological surveillance programme. Results 
of sera collected in 1989 - 91 revealed that the proportion of school age children who were 
susceptible to measles was increasing as a result of reduced exposure to infection. 
Mathematical models, used to interpret the data, demonstrated that the increasing 
susceptibility of school children provided the potential for a major epidemic in the mid 
1990's (Gay et al, 1995). So all children aged 5 to 16 years of age were offered a single 
dose of MR vaccine. The rubella component of the vaccine was included in order to reduce
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the high level of susceptibility to rubella in young adult males and thus reduce the risk of 
transmission from this group to pregnant women. Ninety two percent of children in the 
target cohort (5 to 16 years) were vaccinated.
Another example of the influence of the serological surveillance programme on 
vaccination policy was the adoption of a routine second dose of MMR. Although the 
vaccination campaign had a significant impact on the prevalence of measles and rubella 
antibody in the target cohort (5-16 year olds), a high proportion (-15%) of 2 - 4 year olds 
had low levels (<100 mlU/ml) of antibody to measles both before and after the campaign. 
Also, Gay et al. (1997) showed that up to 15% of 2 to 6 year olds had no detectable 
antibody to mumps. Thus a second dose was added to the schedule providing another 
opportunity for children to be immunised before they start school.
Other countries have adopted similar serological surveillance systems. For example in 
the Netherlands, every five years blood samples donated from a random sample of the 
population are used for surveillance purposes (Esveld, 1994). As well as on-going 
surveillance programmes, periodic serosurveys are beneficial for defining the immunisation 
status of a community, especially in developing countries with meagre resources.
To harmonise and co-ordinate the serological surveillance of communicable diseases in 
Europe, a European Sero-Epidemiological Network has been established (Osborne et al., 
1997). The project has involved serosurveys in eight European countries to measure the 
age-specific prevalence of antibodies to five diseases, including to mumps and rubella 
(Andrews et al., 2000). Thousands of age and sex stratified sera have been collected and 
tested for virus-specific antibodies by ELISA in a national laboratory of each country. 
Although different kits were used in different countries a standardisation procedure was 
developed to allow direct comparison between assay results, and ultimately between the 
epidemiology of these infections under different vaccination programmes.
1.5 Laboratory techniques
A variety of laboratory techniques have been used to demonstrate mumps and rubella 
immunity (Grillner and Bloomberg, 1976; Sato et al., 1978; Morgan-Capner et al., 1979; 
Vaananen and Vaheri, 1979; Kurtz et al., 1980; Popow-Kraupp, 1981; Meurman et al., 
1982; Enders et al., 1985; and Grillner et al., 1985). PRN is generally considered to be the 
most reliable method as it detects neutralising (NT) antibodies. NT antibodies are believed 
to correlate well with immunity in most viral infections. PRN, however, is not suitable for 
testing large numbers of samples as it depends on cell culture so is time consuming and 
relatively expensive. Modified versions of PRN have been developed but these are still
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dependent on cell culture and take several days to complete (Harmsen et al., 1992). HI or
HIG techniques are also believed to correlate well with immunity as they measure a
biological function of the virus-specific antibody, but require considerably less time and
effort to perform than PRN and have been reported to be more sensitive (Albrecht and
Klutch, 1981). HI, however, can give false positive results due to the incomplete removal
of inhibitors of haemagglutination. HIG was initially used to measure mumps and rubella
antibodies for the UK serological surveillance programme, however the ELISA has
recently replaced it (Osborne et al., 2000). ELISAs are quick and easy to perform, benefit
from automation and validated kits and reagents are commercially available so are ideal for
testing large number of samples. Moreover, ELISAs can be used to detect viral antibodies
in non-invasive specimens, such as oral fluid, which are much easier and painless to collect
compared with blood. This factor greatly facilitates subject recruitment for
seroepidemiological studies. In Chapter 2 of this thesis, the development and evaluation of
an 'IgG' antibody capture ELISA (GACELISA) for the detection of mumps-specific IgG in
oral fluid is described.
An oral fluid GACELISA was recently developed and evaluated for rubella-specific IgG 
(Vyse et al, 1999). They demonstrated the sensitivity of the assay was age-dependent: 
compared with serum in those aged 3.5-4 years the assay was 94.8% sensitive but only 
60.8% sensitive in those aged 17-34 years. The lack of sensitivity in the older cohort may 
have reflected waning antibody levels, and highlights the need for more sensitive detection 
systems for the detection of antibodies in non-invasive samples. I-PCR has recently been 
described as a highly sensitive technique for the detection of antigens. It is a modification 
of the ELISA, where the enzyme conjugate is replaced by a DNA molecule that can be 
amplified by PCR. The method offers the potential for highly sensitive assays. In Chapter 
3 of this thesis, the development of an I-PCR assay is described and its use for the detection 
of antibodies to MV is assessed.
As well as sensitivity, another limitation of the ELISA is the difficulty in obtaining 
antigens of reliable quality. Most assays use antigens prepared by concentrating virus 
particles from the maintenance medium of infected cell cultures. Different batches of 
antigens may contain different amounts of viral proteins so careful standardisation is 
required. Moreover, they are potentially infectious and do not distinguish antibodies that 
are of functional significance. NT and HIG assays measure antibodies against surface 
proteins, such as the HN of the MV, which are important for protection. The antigens 
usually employed by ELISAs are from infected cell cultures, so may measure antibodies to
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the surface proteins but also to internal proteins, which are not thought to correlate with 
protection.
To address the problems of using cell culture derived viral antigens, recombinant and 
synthetic proteins have been produced and used as antigens in ELISAs. The advantages of 
using such antigens is that they are non-infectious and can be more easily produced and 
standardised. Moreover they may represent functional epitopes, such as putative NT or HI 
determinants so offer the potential for assay improvements. In Chapter 4 of this thesis, the 
production of recombinant RV fusion proteins using a prokaryotic expression system is 
described and the suitability of these proteins as antigens in ELISA is assessed.
Chapter 2
Development and evaluation of an antibody capture ELISA 
for the detection of mumps-specific IgG in oral fluid
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2.1 Introduction
2.1.1 Oral fluid
Traditionally, serum has been the specimen of choice for detecting antibody to diagnose 
infection or determine immune status. Blood collection, however, is invasive, risky and 
relatively expensive. It requires trained staff and sterile equipment. Oral fluid, by contrast, 
can be collected safely and cheaply, and is more acceptable, especially for population 
immunity studies where large numbers of specimens need to be easily and economically 
obtained, often from children (Figure 2.1) (Mortimer and Parry, 1991).
Figure 2.1 Collection of oral fluid from an infant with an Oracol sponge swab.
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Oral fluid is defined as the fluid obtained by the insertion of absorptive collectors into 
the mouth (Atkinson et al., 1993). Depending on the material it is composed of and the 
location in the oral cavity where the collector is used, the fluid collected is enriched in 
specific components of whole saliva. Fluid found in the oral cavity consists of secretions 
from the salivary glands (mainly the parotid, submandibular and sublingual glands) and 
transudate from the capillary bed, in particular the crevicular fluid that constantly flows 
from the crevice between the gum margin and the teeth. Crevicular fluid is the component 
in saliva that contains the highest concentrations of IgG and IgM. Oral fluid samples in 
which crevicular fluid is well represented are most suitable for antibody detection.
The mean immunoglobulin concentrations found in several salivary components and 
plasma is shown in Table 2.1. It should be noted that the salivary concentrations of 
plasma-derived immunoglobulins vary between individuals depending upon the collection 
methods used and levels of oral health and hygiene.
A drawback of using oral fluid samples is that while specific antibody levels reflect 
those in plasma, concentrations are considerably lower and more variable. This means that 
sensitive assays are required to detect antibody in oral fluid. The assay format most widely 
used for antibody detection in oral fluid is the antibody capture assay.
Table 2.1 Mean immunoglobulin concentrations (mg/L) in plasma and salivary 
components
Specimen
Plasma
Parotid saliva
Crevicular fluid
Whole saliva
IgG
14730
0.36
3500
14.4
IgM
1280
0.43
250
2.1
IgA
2860
39.5
1110
19.4
Sources: Brandtzaeg et al., 1970; Roitt and Lehner, 1983.
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2.1.2 Antibody Capture Assays
The basis of the 'antibody capture' technique is that a single class of human 
immunoglobulin (i.e. IgG, IgM or IgA) in the specimen is captured by an immobilised, 
class-specific anti-immunoglobulin. Specific antibody is then detected by the addition of 
an antigen and, for example, a mouse monoclonal antibody to the antigen and a labelled 
anti-mouse immunoglobulin. The label may be an enzyme that produces a colour signal in 
the presence of substrate or a radioisotope such as I
The antibody capture assay differs from other assay configurations (i.e. indirect, 
sandwich and competitive) in that the strength of the signal is not dependent on the 
concentration of specific antibody in the sample, but on the proportion of the captured 
immunoglobulin that is specific for the antigen. Since oral fluid includes plasma transudate 
as the predominant source of immunoglobulin, the ratio of specific to total immunoglobulin 
is similar in both serum and oral fluid. Hence, as long as the test specimen contains 
sufficient IgG to saturate the anti-IgG binding sites, the signal obtained should be similar 
whichever sample is used (Mortimer and Parry, 1988; Parry, 1993; Nishanian et a/., 1998). 
Antibody capture assays were first described by Flehmig et al. (1979) and Duermeyer et 
al. (1979) for the detection of IgM antibodies against hepatitis A virus (HAV). They are 
now widely used mainly in the diagnosis of acute virus infection but also in the 
determination of immune status. Originally, these assays were intended for use with 
serum. However, when the advantages of oral fluid sampling were realised, assay 
protocols were modified appropriately. Parry et al. (1987) were the first to describe IgG 
antibody capture radioimmunoassays (GACRIAs) and GACELISAs for the detection of 
specific antibodies to human immunodeficiency virus (HIV), RV, HAV and the core 
antigen of hepatitis B virus (HBV) in saliva. It is worth noting that most of the early 
developmental work used whole saliva that was collected by being dribbled into a sterile, 
wide mouthed container. However, subjects found dribbling distasteful and not 
infrequently either sputum specimens or samples with insufficient volume were received. 
Also, pipetting untreated saliva was difficult. This led to the development of the 
proprietary oral fluid collection devices featured in Table 2.2 and Figure 2.2.
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Table 2.2 Characteristics of four oral fluid collection devices
Collection 
Device
Salivette®
OraSure®
Omni-SAL®
Oracol
Description
Chew cotton wool for 30 to 45 
seconds or place under tongue 
for 1 minute
Move pad gently along gum 
twice. Place against lower gum 
on 1 side and keep stationary for 
2 minutes
Place pad under tongue and 
keep until indicator of device 
turns blue
Rub sponge firmly along the 
base of the gums (inside and 
out) of the upper and lower jaw, 
for 1 minute, using an action 
similar to tooth brushing
Manufacturer
Sarstedt
Epitope
Saliva Diagnostic 
Systems
Malvern Medical 
Developments
Unit 
Cost3
£036
£2'50
£2'20
£0'50
3Unit costs as of November 2001
Figure 2.2 Four oral fluid collection devices
From left to right: Salivette , OraSure , OminSal, and Oracol.
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Antibody capture assays for oral fluid have also been developed for the detection of 
virus specific IgG to measles virus (Perry et at., 1993), EBV (Vyse et al., 1997) and 
parvovirus B19 (Rice and Cohen, 1996) and for specific IgM in patients with recent 
hepatitis A or B (Parry et al, 1989), measles, mumps, rubella (Perry et al, 1993) and 
parvo virus B19 infection (Cubel et al., 1996). Many of these assays were developed as 
radioimmunoassays (RIAs), which have the advantages of a wide dynamic range, 
quantification and sensitive detection of radioactivity by a gamma counter. However, there 
are practical disadvantages associated with R1A. Not only does radiolabelling produce 
hazardous radioactive waste, but the technique is not easily transferable between 
laboratories. Unfortunately, however, the substitution of an enzyme-labelled conjugate for 
a 125I-labelled conjugate has not in many cases resulted in an ELISA with the same 
sensitivity as RIA when testing oral fluid (Parry et al., 1987).
2.1.3 Oral fluid testing
Oral fluid testing has been most useful for epidemiological surveillance. RIAs that 
reliably detect measles, mumps and rubella-specific IgM in oral fluid are used to confirm 
disease notifications in the UK (Brown et al., 1994). In the context of virus specific-IgG, 
most success has been with HIY tests. Several oral fluid screening assays for IgG 
antibodies to HIV-1 have been developed and commercial test kits have become available 
that have been reported to be sensitive and specific (Malamud, 1997). The development of 
oral fluid IgG screening assays for other viral infections has been slow in part due to the 
lack of demand (i.e. for commercial reasons) but also due to the lack of availability of 
assays that are sensitive enough to replace serum assays. However, the findings of recent 
studies have been promising and moved us closer to realising the wider use of oral fluid 
surveys of viral specific IgG. For example, novel oral fluid GACELISA assays that are 
sensitive and specific enough to substitute for serum assays have been developed and 
evaluated for measles (Nigatu et al, 1999), rubella (Vyse et al., 1999) and EBV (Sheppard 
et al., 2001). These assays employ a FITC/anti-FITC amplification step which 
compensates for the less sensitive spectrophotometric detection in ELISA compared to 
radioactive counting and the smaller surface area available for binding on the microtitre 
ELISA plate compared to that on the polystyrene bead used in RIA.
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2.1.4 Detection of mumps antibodies in oral fluid
To date, there have been only three reports of assays to detect mumps antibodies in 
saliva/oral fluid. Frankova and Sixtova (1987) used indirect immunofluorescence and 
indirect ELISA to detect mumps-specific IgM in saliva but they were unable to identify 
mumps cases reliably. Perry et al. (1993) developed a saliva-based IgM capture 
radioimmunoassay (MACRIA) and a GACRIA. The sensitivity of the MACRIA was 
100% but for the mumps GACRIA it was only -50%, compared to the equivalent serum 
assay. Thieme et al. (1994) used a modified indirect commercial ELISA to detect mumps- 
specific IgG in oral fluid collected using the OraSure® device and found the assay was 
94.2% sensitive for subjects over 18 years old, however only 75% sensitive for subjects 
younger than 18 years.
In this study, a GACELISA employing recombinant mumps nucleoprotein-associated 
antigen (rNP) and a mouse anti-rNP MAb conjugate was developed for the detection of 
mumps-specific IgG in oral fluid. This is the first time this method has been developed for 
mumps-specific IgG. The assay was evaluated by comparison of results from testing 
serum-oral fluid paired samples, as well as the more recently described statistical approach, 
mixture modelling (Parker et al., 1990). Mixture modelling treats results from a sample of 
individuals as a mixture of different populations. Models are used to fit the distribution of 
results into seronegative and seropositive populations without first having to identify an 
uninfected population, and optimum cut-off values can be assigned that give the required 
balance between sensitivity and specificity. These models have been particularly useful for 
estimating antibody prevalence in age-related serological surveys where the assay gives 
results with two overlapping distributions for the negatives and positives (Gay, 1996).
2. Material and Methods
2.2 Material and Methods
2.2.1 Oral fluid collection and processing
Oral fluid was collected using the Oracol (Malvern Medical Developments, Barbourne, 
Worcester, UK) and OraSure® (Epitope, Inc., Beaverton, USA) collection devices, 
according to the manufacturers instructions (Table 2.2). The Oracol consists of a 2 x 1.5cm 
polystyrene sponge on a 10 cm plastic stick, whereas the OraSure® consists of a 3 x 1cm 
flat pad of absorbent material supported by a 10 cm plastic stick (Figure 2.2). Both devices 
are provided with a stoppered tube that, in the case of OraSure®, contains transport medium 
with preservative.
After the collection of oral fluid, the devices were placed into the appropriate transport 
container and labelled with a unique identification number. Collected samples were 
transported to the laboratory where the oral fluid was extracted as shown in Table 2.3. 
Samples were stored in labelled screw capped microtubes at - 20°C until required for 
testing.
Table 2.3 Extraction of oral fluid
Collection Device Extraction method
Oracol One millilitre of transport medium was added to the 
collection tube. The swab was agitated manually until 
foaming of transport medium and then removed from the 
tube using a twisting motion to extract as much liquid as 
possible. The swab was inverted so that the sponge was at 
the top and the cap was replaced. The tube containing the 
swab was centrifuged at 2000 x g for 5 min. The sponge 
was discarded and the extracted fluid was pipetted into a 
labelled screw-capped storage tube.
OraSure" The small plastic tip at the base of the OraSure tube was
broken off and discarded. The OraSure tube was 
centrifuged at 2500 x g for 10 min within a test tube. The 
extracted fluid was pipetted into a labelled screw-capped 
storage tube.
a Oracol extracted as described by Brown et al. (1994); OraSure® extracted according to 
the manufacturers instructions. 
b See Appendix A.
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2.2.2 Samples
(i) Serum/oral fluid pairs
1. Six pairs were provided by Enteric, Respiratory and Neurological Virus Laboratory 
(ERNVL) staff for optimisation of the GACELISA.
2. One hundred and twenty two pairs were collected from healthy members of staff at the 
SRMD and CDSC at Colindale. The PHLS ethics committee approved the study 
procedures and the consent forms (Appendix B). The study was anonymised. Subjects 
were over 18 years of age and gave written consent. Five millilitres of venous blood was 
collected from each volunteer on day one by medical personnel using the Vacutainer 
system. Six oral fluid samples (five Oracol and one OraSure®) were self-collected from 
each volunteer: three Oracol swabs were self-collected on day one in the presence of 
laboratory personnel (swab 1 was collected from one side of the mouth, swab 2 from the 
other side of the mouth and swab 3 from both sides of the mouth); and two Oracol and the 
OraSure® were self-collected on day two in the absence of laboratory personnel (swab 4 
was collected from one side of the mouth, swab 5 from the other side of the mouth and 
swab 6 (OraSure®) from either side of the mouth). The swabs were labelled 1 - 6 as taken. 
Upon receipt in the laboratory the oral fluid was processed as described above and the 
blood was allowed to clot and then centrifuged for 10 min at 3000 x g. The serum was 
collected and frozen at - 20 °C until use.
(ii) Oral fluid
Oral fluid samples were selected at random from those submitted to ERNVL for MMR 
testing. A total of 923 samples from persons aged 0.7 - 99 years were tested, and 
individual results were aggregated into four age groups: group 1, 0.7 - 1.4 years (n = 210); 
group 2, 1.41 - 8.99 years (n = 159); group 3, 9 - 19.99 years (n = 196); and group 4, over 
20 years (n = 358).
2.2.3 Total IgG assay
The total IgG content of oral fluid specimens was measured using an indirect ELISA as 
previously described (Connell et a/., 1990). Oral fluid samples were screened at a dilution 
of 1/10 and 1/100.
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2.2.4 Preparation of mouse immunoglobulin column
Mouse immunoglobulin (Ig) was prepared by precipitation with an equal volume of 
ammonium sulphate [(NH^SO^ for 1 h, followed by centrifugation at 4000 x g for 15 
min. The precipitate was dissolved in 0.1 M sodium bicarbonate buffer, pH 8.3 (Appendix 
A) and excess salts were removed by gel filtration through a PD-10 column containing 
Sephadex G-25 (Amersham Pharmacia Biotech, High Wycombe, U.K.). The crude Ig 
fraction containing approximately 60 mg of protein in 0.1 M sodium bicarbonate buffer, pH 
8.3 was added to 0.73 g of swollen cyanogen bromide-activiated sepharose 4B (CNBr-S4B; 
Amersham Pharmacia Biotech), which had been washed with 10 ml of 1 mM HC1 to 
remove preservatives as recommended by the manufacturers. After 2 h at 37°C on a 
circular rotator, the mix was added to an empty PD-10 column (Amersham Pharmacia 
Biotech). The column was centrifuged at 2500 rpm for 5 min and the optical density (OD) 
at 280 nm of the eluate was measured to estimate the percentage of bound antibody 
(~50mg). The column contents were then washed with 0.1 M sodium bicarbonate buffer, 
added to 20 ml of 0.1 M Tris-HCL, pH 8.0 (Appendix A) and allowed to mix for 1 h at 
37°C on a circular rotator and then overnight (ON) at 4°C to block any remaining active 
groups. The column was packed by centrifugation at 2500 rpm and washed with 0.1 M 
Tris-HCl, pH 8.0 containing 0.5 M NaCl.
2.2.5 Purification of anti-human IgG on a mouse Ig column
One millilitre of rabbit anti-human IgG (Dako) was slowly applied to a mouse Ig 
column equilibrated with PBS azide (Appendix A). The column was incubated for 1 h at 
RT to allow cross-reacting antibodies to adsorb and then washed to remove unbound 
material until no protein was detected in the eluent, as determined by UV absorbance at 
280 nm. The column was eluted with 10 column volumes of 0.1 M glycine-HCl, pH 2.5 
(Appendix A) and re-equilibrated with PBS azide.
2.2.6 Mumps IgG antibody capture ELISA (GACELISA)
After a series of experiments to optimise the assay conditions the following procedure 
was used: microtitre plate wells (Nunc MaxiSorp , Life Technologies, Paisley, U.K.) 
were incubated with 10 /-ig/ml of rabbit anti-human IgG (Dako, Ely, U.K.), pre-absorbed on 
a mouse Ig column, in 0.05 M sodium carbonate buffer, pH 9.6 (Appendix A) overnight at 
4 °C and then for 2 h at 37 °C in a moist container. The wells were aspirated and blocked
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with 5 % SoluPro (Dynagel Inc., Calumet City, IL, USA) for 2 h at 37 °C in a moist 
container. After aspirating, the wells were left to dry ON at 37 
Coated wells were incubated at 37°C sequentially with 100 /zl of the following: 
undiluted oral fluid or a 1/200 dilution of serum in diluent A (Appendix A) for 30 min; 50 
ng/ml of rNP (Microimmune Ltd., Brentford, U.K.) in diluent A for 1 h; and 0.2 /ig/ml of 
mouse anti-rNP horseradish peroxidase-labelled monoclonal antibody (anti-rNP-HRP; 
Microimmune Ltd.) in diluent A for 30 min. During the incubation steps the wells were 
agitated on an iEMS Incubator/Shaker (Thermo Labsystems, Helsinki, Finland) and 
between each stage of the assay the wells were washed four times with PBS containing 
0.05% T20 (PBST; Appendix A). Finally, 100 /zl of 3, 3', 5', 5' - tetramethylbenzidine 
(TMB) substrate solution (Microimmune Ltd.) was added to each well and the plate was 
incubated at room temperature (RT) for 30 min. The reaction was stopped by the addition 
of 100 n\ of 0.5 M hydrochloric acid (HC1) and the OD was read at 450 nm with 620 nm 
reference on an ELISA plate reader (Thermo Labsystems iEMS-MF), unless otherwise 
stated. Duplicate negative and positive serum controls were run in parallel with test 
samples.
For the optimisation experiments, test OD results were divided by the mean OD of the 
negative serum control to give a test to negative ratio (T/N), unless stated otherwise. The 
use of T/N is conventional in the analysis of ELISA data (Tijssen, 1985). For the final 
protocol, test OD results were converted to logT/N (as logarithmic transformation made the 
data more normally distributed). A schematic diagram of the mumps GACELISA is shown 
in Figure 2.3.
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Anti-rNP-HRP
rNP
Human anti-mumps IgG (test sample)
Anti-human IgG
Microtitre plate well
Immobilised anti-human IgG was used to capture human IgG antibodies in oral fluid. 
Mumps-specific IgG was detected by the sequential addition of rNP, anti-rNP-HRP and 
TMB substrate. Spectrophometric readings were taken after the reaction was stopped with 
0.5 M hydrochloric acid.
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Mean concentrations of total IgG in oral fluid were compared using analysis of variance 
and paired t-tests. Paired t-tests were also used to determine if there was a significant 
difference between the T/N values of samples analysed in the optimisation experiments.
The 95% confidence intervals for the differences between duplicate serum control 
results of five representative assays were calculated to establish an acceptable difference 
between the duplicate controls in order to validate further assay runs.
The relationship between oral fluid and and serum OD values was measured using the 
Pearsons correlation co-efficient.
Mixture models using normal distributions were fitted to the GACELISA results from 
oral fluids submitted for MMR testing to estimate optimal cut-off values and assay 
sensitivity and specificity. The mean, standard deviation (SD) and prevalence of results in 
the different populations were obtained using the multinominal maximum likelihood 
method (Parker et al. 1990).
A series of experiments were performed to determine the optimal reagents and 
conditions for the GACELISA. These are described below.
Three commercial preparations, rabbit and goat anti-human IgG from Dako (Ely, 
Cambridge, U.K.) and rabbit anti-human IgG from Chemicon International Inc. (Temecula, 
California, U.S.A.), were compared using oral fluid samples collected from staff who were 
negative (n = 1) or positive (n = 3) for mumps-specific IgG in serum. As shown in Figure 
2.4, the best T/N values were obtained when either of the rabbit anti-human IgG 
preparations were used; no significant difference (p = 0.41) in the T/N values of samples 
was observed. In further experiments, the rabbit anti-human IgG preparation from Dako 
was employed as this was being used for other assays in the laboratory.
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'.
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Microtitre plate wells coated with 1 jLig/ml of anti-human IgG in 0.05 M sodium carbonate 
buffer (pH 9.6) were blocked with 5% SoluPro and incubated at 37 °C with 100 /d of the 
following: neat oral fluid or 1/200 dilution of serum in diluent B (Appendix A) for 30 min; 
0.1 jig/ml of rNP in diluent B for 1 h; and 0.2 jig/ml of anti-rNP-HRP in diluent B for 30 
min. Wells were washed four times with PBST between incubations. Bound conjugate 
was detected by incubating wells with 100 /*! of TMB for 30 min at RT and the reaction 
was stopped with 100 p\ of 0.5 M HC1. Samples were tested in duplicate and T/N values 
were calculated by dividing test OD results by the OD results of the negative control 
serum. Sample 1 was from a subject negative for mumps-specific IgG in serum, while 
samples 2-4 were from mumps-specific IgG positive subjects. Error bars represent one 
SD.
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Initial experiments revealed false positive reactions in anti-human IgG coated wells that 
did not receive serum, which were not detected in wells that received negative serum. This 
was due to the binding of the mouse anti-rNP-HRP conjugate to the rabbit anti-human IgG 
coated on the solid phase ('no antigen' control wells). To overcome this problem, the 
commercial rabbit anti-human IgG preparation was applied to a mouse Ig column to 
remove cross-reacting antibodies (see 2.2.5). The elution profile of the absorption is shown 
in Figure 2.5. The first peak (wash) represented antibody that did not adsorb to the column, 
while the second peak (elution) represented antibody that cross-reacted with mouse Ig. 
After the adsorption, the 'wash' and 'elution' fractions were separately pooled, coated onto 
mictrotitre plate wells and reacted with anti-rNP-HRP conjugate. Only background signals 
were detected in wells coated with the pooled wash fraction whereas high signals were 
observed in wells coated with the pooled elution fraction (data not shown).
2.5 
2.5
2 -
1.5 -
OD 280nm
Wash
0.1Mglycine-HCl,pH2.5
Elution
11 13 15 17 19
One millilitre (1.5 mg) of rabbit anti-human IgG (Dako) was applied to a mouse Ig column. 
The column was incubated for 1 h at RT to allow cross-reacting antibodies to adsorb and 
then washed to remove unbound material. The column was eluted with 0.1 M glycine-HCl, 
pH 2.5. One millilitre wash and elution fractions were collected and their UV absorbance 
measured at 280 nm.
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The optimal concentration of absorbed anti-human IgG for coating microtire plate wells 
was determined using oral fluid samples from staff that were negative or positive for 
mumps-specific IgG in serum. As shown in Figure 2.6, the T/N values for the positive oral 
fluid samples, especially the weak positive samples, gradually increased up to 10 /*g/ml of 
immobilised anti-human IgG, then plateaued. Thus, in further experiments anti-human IgG 
was coated on microtire plate wells at a concentration of 10 jug/ml.
T/N 
Negative Positive
T/N
0.06 10
Anti-human IgG (/-tg/ml)
Microtitre plate wells coated with 0.06 /*g/ml to 40 (Jig/ml of absorbed anti-human IgG in 
0.05 M sodium carbonate buffer (pH 9.6) were blocked and then incubated with 100 JJL\ of 
neat oral fluid collected from staff negative (n = 1) and positive (n = 4) for mumps-specific 
IgG in serum. Other assay conditions were as those described in Figure 2.4. T/N values 
were calculated by dividing the test OD of single samples by the negative control ODs.
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Initially BSA was used as a blocking agent in the assay diluent. However relatively 
high levels of non-specific binding were observed in the presence of samples negative for 
mumps-specific IgG (i.e. mean serum negative OD = 0.11; mean oral fluid negative OD = 
0.19). To overcome this problem, 10% PCS was added to the assay diluent. In the 
presence of PCS, the binding with negative samples was greatly reduced (i.e. mean serum 
negative OD = 0.05; mean oral fluid negative OD = 0.07) whereas a relatively lower 
reduction in binding with positive samples was observed (i.e. mean oral fluid positive OD 
= 0.87 without PCS versus 0.64 with PCS), thus giving higher T/N values for positive 
samples (T/N = 12.8 versus 7.9 respectively).
As mentioned in the introduction to this chapter, GACELISA's employing the 
FITC/anti-FITC amplification system have been developed for the detection of rubella and 
measles-specific IgG in oral fluid. The availabilty of a FITC-labelled MAb directed against 
mumps NP (anti-NP-FITC) and an anti-FITC-HRP conjugate enabled an anti-NP- 
FITC/anti-FITC-HRP detection system to be investigated as an alternative to using the anti- 
rNP-HRP conjugate in the GACELISA. Wells coated with rNP were reacted with 
doubling dilutions of anti-NP-FITC conjugate, which was detected using anti-FITC-HRP. 
As shown in Figure 2.7, the dilution of conjugate required to produce an OD of 1 - 2 was 
relatively low (1/400 - 1/800). Under similar conditions, the anti-rNP-HRP conjugate 
produced much higher OD values (data not shown). To establish whether the low OD 
values were a reflection of the low reactivity of the anti-FITC-HRP conjugate, doubling 
dilutions of anti-FITC-HRP were reacted with immobilised BSA-FITC (Microimmune 
Ltd.), and BSA as a control. As shown in Figure 2.8, even at very high dilutions (1/12800) 
the anti-FITC-HRP produced high OD values of 1 - 2. This suggested that the low OD 
values were a result of the low reactivity of the anti-NP-FITC conjugate. This conjugate 
was not used in further experiments.
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Microtire plate wells coated with 1 /xg/ml of rNP in PBS azide were blocked and incubated 
with 100 ill of doubling dilutions of anti-NP-FITC in diluent B for 30 min at 37 °C. After 
washing, wells were incubated with 100 jid of anti-FITC-HRP in diluent B for 30 min at 
37°C. Other conditions were as those described in Figure 2.4. OD results of single samples 
were plotted against dilution of anti-NP-FITC.
OD 3 H 
450/620nm
Blank 400 800 1600 3200 6400 12800 
Anti-FITC-HRP (dilution factor)
Microtire plate wells were incubated with 1 /ig/ml BSA-FITC (Microimmune Ltd.) for 18 
hr at 37 °C and then for 2 h at 37 °C. Wells were blocked and incubated with 100 fi\ of 
doubling dilutions of anti-FITC-HRP for 30 min at 37°C. Bound conjugate was detected as 
described in Figure 2.4. OD results of single samples were plotted against dilution of anti- 
FITC-HRP.
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Mumps serum and oral fluid GACELISA 'checkerboard' titrations of immobilised rNP 
and anti-rNP-HRP conjugate were performed using negative and low positive serum 
samples, and a pool of negative and positive oral fluid. A pool of oral fluid was used to 
obtain sufficient material for the experiment. The concentrations of antigen investigated 
for both the serum and oral fluid assay were 5 ng/ml to 1 /ig/ml. The concentrations of 
conjugate investigated for the serum GACELISA were 0.025 /ig/ml to 0.8 /ig/ml, and 0.025 
^g/ml to 0.4 jLtg/ml for the oral fluid GACELISA. As shown in Figure 2.9(a), for the serum 
GACELISA the highest T/N values were observed at an antigen concentration of 10 ng/ml 
and a conjugate concentration of 0.2 /-ig/ml, although there was no significant difference in 
the T/N values between 5 ng/ml - 0.1/ig/ml of antigen (p = 0.22) and 0.1 - 0.4 /ig/ml of 
conjugate (p = 0.42). In Figure 2.9b, the highest T/N values in the oral fluid GACELISA 
were observed at an antigen concentration of 50 ng/ml and conjugate concentration of 0.4 
/-ig/ml, although there was no significant difference in T/N values between 0.2 and 0.4 
jug/ml of conjugate (p = 0.56). As a result of these findings, in further experiments the 
concentrations of antigen and conjugate used for the serum and oral fluid GACELISA were 
50 ng/ml and 0.2 /ig/ml respectively.
The effect of shaking wells during the incubation steps was then investigated. Although 
only marginally higher T/N values were observed when the wells were shaken during the 
sample, antigen and conjugate incubation steps (i.e. serum T/N =11.8 versus 10.5; oral 
fluid T/N = 6.3 versus 5.5) shaking was employed in subsequent experiments.
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Microtitre plate wells coated with 10 /zg/ml of absorbed rabbit anti-human IgG in 0.05M 
sodium carbonate buffer (pH 9.6) were incubated with 100 /*! of 1/200 dilution of negative 
and positive serum or 100 /JL\ of neat, pooled negative and positive oral fluid in diluent B for 
30 min at 37°C. After washing wells were incubated with titrations of rNP and anti-rNP- 
HRP as indicated. Other conditions were as described in Figure 2.4. The negative oral 
fluid samples were from unvaccinated infants and the positive oral fluid samples were from 
>30 year olds. T/N values were calculated by dividing the test ODs of single samples by 
the negative control ODs.
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The total IgG concentrations of 300 oral fluid samples self-collected by 50 volunteers (6 
swabs/subject) were used for a comparative analysis of sample quality (Table 2.4). The 
statistical comparisons showed that the mean titre (MT) of total IgG in oral fluid did not 
significantly differ between different sides of the mouth, whether collected on day 1 (p = 
0.605) or day 2 (p = 0.874). Similarly, the MT of total IgG did not significantly differ 
whether oral fluid was collected from one side or both (side 1 + side 2) sides of the mouth 
(swab 2 v swab 3; p = 0.983). However, significantly higher (p = O.001) MT were 
observed on day 2 (unsupervised collection) compared with day 1 (supervised collection). 
Also, the MT of total IgG in oral fluid was significantly higher (swab 5 v swab 6; p = 
0.033) using the Oracol compared with the OraSure® device. From these findings, the oral 
fluid collected using the Oracol device was used in further experiments. Since no 
significant difference was observed between samples taken from different sides of the 
mouth it was not necessary to pool the samples prior to testing.
Oral Fluid 
(n=300)
Swabl
Swab 2
Swab 3
Swab 4
Swab 5
Swab 6
Collection 
Device
Oracol
Oracol
Oracol
Oracol
Oracol
OraSure®
Day of 
collection
1
1
1
2
2
2
Collected from one or 
both sides of the
Sidel
Side 2
Side 1 + Side 2
Sidel
Side 2
Side 1 or Side 2
Supervised
Yes
Yes
Yes
No
No
No
Total IgG mean 
mg/L (range)
19.9(6.4-81.2)
24.4(8.3-101.2)
24.4(6.2-144.9)
36.5(7.3-145.7)
35.7(5.4-133.6)
26.7(2.4-145.0)
p value
p = 0.605a
p = 0.98" 
p = <0.001 c
p = 0.874d
p - 0.033e
Comparison of total IgG titres from swab 1 with swab 2. 
b Comparison of total IgG titres from swab 2 with swab 3. 
0 Comparison of total IgG titres from swab 2 with swab 5. 
d Comparison of total IgG titres from swab 4 with swab 5. 
e Comparison of total IgG titres from Oracol (swab 5) with OraSure (swab 6).
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To determine the reproducibility of the GACELISA four serum and eight oral fluid 
samples were assayed six times on the same test plate (intra-assay variation), and on 
different plates on five separate occasions (inter-assay variation). The samples were 
arranged in the 96-well plates in a systematic way to avoid samples appearing in the same 
position in the different columns. Table 2.5 shows the mean OD values, SDs and 95% 
confidence intervals for the replicates. As expected the inter-assay variation was greater 
than the intra-assay variation; 95% of results were within 27% of the true mean between 
wells on different plates and within 11% of the true mean between wells on the same plate. 
These low values indicate that the assay was highly reproducible.
2.5 
Sample 
Noa
1
2
3
4
5
6
7
8
9
10
11
12
Intra-assay variation
Geometric mean 
OD (n = 6)
0.051
0.59
0.025
3.238
0.175
1.077
0.486
2.229
0.419
0.524.
0.058
0.0469
Geometric mean 
log OD (n = 6)
-1.29
-0.23
-1.61
0.51
-0.76
0.03
-0.31
0.35
-0.38
-0.28
-1.24
-0.33
SDb 
logOD
0.032
0.021
0.047
0.008
0.017
0.022
0.012
0.013
0.022
0.006
0.045
0.020
Average
95% CIC
(+/-)
15.9
0.3
24.0
3.8
8.3
10.5
5.8
6.1
10.5
2.6
23.1
9.5
11%
Inter-assay variation
Geometric mean 
OD (n = 6)
0.042
0.50
0.024
2.835
0.147
0.878
0.424
1.937
0.368
0.452
0.055
0.419
Geometric mean 
log OD (n = 6)
-1.376
-0.305
-1.621
0.451
-0.837
-0.059
-0.374
0.286
-0.439
-0.348
-1.261
-0.380
SDb 
logOD
0.056
0.060
0.042
0.044
0.065
0.057
0.040
0.037
0.070
0.059
0.043
0.052
Average
95% CIC
(+/-)
29.6
31.7
21.3
22.4
35.1
29.9
20.1
18.6
38.0
31.4
21.6
26.8
27%
a Sample numbers 1 - 4 and 5-12 were serum and oral fluid samples respectively.
b SD denotes standard deviation.
c 95% CI denotes the 95% confidence interval around the mean OD.
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An experiment was performed to determine a way of evaluating the validity of each 
assay run. The OD results (log scale) of four serum controls in five different assay runs 
were used to determine a 95% confidence interval for the differences between duplicates 
(Table 2.6). For the 20 sets of results, the SD of the differences was 0.05 (log scale). Thus, 
95% of acceptable results were expected to fall within 0.103 (log scale) of one another, 
which was a 27% difference (i.e.100103 = 1.27). Assays with differences in the serum 
controls of less than 27% were accepted.
Test
No.
1
2
3
4
5
Serum Control
1
2
3
4
1
2
3
4
1
2
3
4
1
2
3
4
1
2
3
4
OD1
0.042
0.453
0.027
2.423
0.045
0.462
0.027
2.399
0.048
0.448
0.027
2.667
0.046
0.5
0.028
2.838
0.039
0.42
0.026
2.35
OD2
0.049
0.462
0.031
2.276
0.048
0.448
0.027
2.667
0.048
0.448
0.027
2.667
0.064
0.554
0.038
2.784
0.038
0.428
0.023
2.101
log OD1
-1.377
-0.344
-1.569
0.384
-1.347
-0.335
-1.569
0.380
-1.319
-0.349
-1.569
0.426
-1.337
-0.301
-1.553
0.453
-1.409
-0.377
-1.585
0.371
log OD 2
-1.310
-0.335
-1.509
0.357
-1.319
-0.349
-1.569
0.426
-1.319
-0.349
-1.569
0.426
-1.194
-0.256
-1.420
0.445
-1.420
-0.369
-1.638
0.322
Difference3
-0.067
-0.009
-0.060
0.027
-0.028
0.013
0.000
-0.046
0.000
0.000
0.000
0.000
-0.143
-0.045
-0.133
0.008
0.011
-0.008
0.053
0.049
Difference was log OD 1 - log OD 2.
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The Biostat (Bio-Stat Diagnostic Systems, Stockport, UK) and Behring (Behring 
Enzygnost, Marburg, Germany) commercial ELISAs for the detection of antibodies to 
mumps were investigated. The cut-off values used were as those recommended by the 
manufacturers. One hundred and twenty-two samples were tested and the results are 
shown in Table 2.7. Of the 122 samples, 87 were positive and 7 were negative by both 
assays. Eighteen samples that were Behring equivocal were positive by the Biostat assay 
and one Biostat equivocal was Behring negative. Also, nine positive Biostat samples were 
Behring negative. These findings suggest that the Biostat assay was either more sensitive 
or less specific than the Behring assay. A scatter plot of the results showed the assays 
correlated well (r = 0.96), particularly for positive samples (Figure 2.10).
BIOSTAT
Equivocal
Negative
Positive
Total
BEHRING
Equivocal
-
-
18
18
Negative
1
7
9
17
Positive
-
-
87
87
Total
1
7
114
122
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Behring log(OD)
0.5
-0.5
-1.5
-2.5
-3.5
-2.0 -1.5 -1.0 -0.5 0.0
Biostat log(OD)
0.5 1.0
The Behring OD results were plotted against the Biostat OD results (log scale). The dotted 
lines represent the equivocal (red lines) and positive (green lines) cut-off values for the 
assays.
The mumps GACELISA with serum and oral fluid was initially evaluated using the 122 
serum-oral fluid pairs, where the sera had been previously tested using the commercial 
assays described above. For both evaluations, the GACELISA results were compared with 
the serum results obtained using the Biostat assay (as this appeared to be more sensitive 
than the Behring assay). Table 2.8 shows how the cut-off values were calculated.
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Samples
1
2
3
4
5
6
7
Standard deviation
Mean serum control
Cut-off0
GACELISA
Serum
0.051
0.036
0.124
0.033
0.033
0.076
0.041
0.0335
0.028
0.128
Oral fluid
0.043
0.026
0.053
0.024
0.024
0.055
0.032
0.0135
0.027
0.068
aCut-off = mean serum or oral fluid control + 3 SD
For the serum GACELISA, 118 of the 122 samples gave the same results as the Biostat 
ELISA (Table 2.9). One sample was equivocal by the Biostat assay and negative using the 
GACELISA, and three samples were Biostat positive and GACELISA negative, giving an 
overall sensitivity and specificity for the GACELISA of 97% and 100% respectively. A 
scatter plot of the results (Figure 2.1 la) showed the assays correlated well (r = 0.93). For 
the oral fluid GACELISA, 121 of the 122 oral fluids gave the same results as the Biostat 
assay based on serum resulting in 100% sensitivity and specificity. One sample that was 
Biostat equivocal and GACELISA negative was not included in the analysis. A scatter plot 
of the results (Figure 2.1 Ib) showed relatively good correlation (r = 0.90) between the oral 
fluid and serum mumps IgG levels.
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Table 2.9 Comparison of Biostat assay and GACELISA with (a) serum and (b) oral 
fluid using 122 serum-oral fluid pairs collected from staff
(a) Serum GACELISA
BIOSTAT
Equivocal
Negative
Positive
Total
GACELISA
Negative
1
7
3
11
Positive
-
-
Ill
111
Total
1
7
114
122
(b) Oral fluid GACELISA
BIOSTAT
Equivocal
Negative
Positive
Total
GACELISA
Negative
1
7
-
8
Positive
-
-
114
114
Total
1
7
114
122
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1.0
GACELISA 
log(OD)
-1.0 -
-2.0
-2.0 -1.5 -1.0 -0.5 0.0
Biostat log(OD)
0.5 1.0
GACELISA 
log(OD)
-1.0 -
-2.0
Biostat log(OD)
The GACELISA (a) serum and (b) oral fluid OD results were plotted against the Biostat 
OD results (log scale). The dotted lines represent the equivocal (red lines) and positive 
(green lines) cut-off values for the assays.
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2.3.7 
In the previous evaluation using serum-oral fluid pairs, only seven of the 122 subjects 
were negative for mumps-specific IgG. This was not surprising as the samples were 
obtained from staff volunteers who were over 18 years of age. One would expect them to 
have been exposed to mumps. However, the low numbers of negatives means the 
specificity estimate was not reliable. To further investigate the performance characteristics 
of the assay, oral fluid samples from 923 subjects aged 0.7 - 99 years were tested by the 
GACELISA and the results were analysed using mixture modelling. Mixture modelling 
was used as it does not require the antibody status of specimens to be known. Models were 
fitted to the distribution of results and optimal cut-off values that maximised assay 
sensitivity and specificity were estimated. The prevalence of antibody in each category of 
the study population was also estimated. It should be noted, however, that the samples 
used for the study were not a random sample of the population. They were selected at 
random from oral fluids submitted to ERNVL for MMR testing.
For the analysis, the GACELISA results were categorised by age (group 1, 0.7 -1.4 
years; group 2, 1.41 - 8.99 years, group 3, 9 - 19.9 years, and group 4, > 20 years), 
vaccination and mumps-specific IgM status (Table 2.10). Samples from infants aged 0.7 - 
1.4 years were chosen to provide a negative population as they were unlikely to have been 
vaccinated against mumps and would have lost their maternal antibodies. Children aged 
1.41 - 8.99 years may have received two doses of MMR (as the two-dose schedule was 
introduced in 1996) whereas those aged 9 - 19.99 years most likely only received one dose. 
Those greater than 20 years would not have routinely been offered vaccination but would 
most likely have been exposed to natural mumps infection.
Of the study population, 127 subjects were mumps-specific IgM positive; 37 (29%) had 
received one dose and ten (8%) had received two doses of MMR vaccine (Table 2.10). 
Only one of the IgM positive subjects was under 9 years. Of the IgM negative subjects, 
196 were under 20 years and vaccinated; 249 were under 20 years and unvaccinated (most 
of these were under 1.4 years); 294 were over 20 years and unvaccinated; 16 were over 20 
years and vaccinated; and for 41 subjects it was unclear if they had been vaccinated.
Status3
IgM -ve 4- unvaccinated
IgM -ve + vaccinated (2 doses)
IgM +ve + unvaccinated
IgM +ve + vaccinated (2 doses)
Unknown
Total
Age Group 
(range)
1 
(0-1.4 years)
197
2
0
0
11
210
2 
(1.41-8.99 years)
30
120(67)
1
0
8
159
3 
(8.99-19.99 years)
22
74
34
44(8)
22
196
4 
(> 20 years)
294
16(6)
45
3(2)
 
358
Total
584
212(73)
80
47(10)
41
923
a!gM status was determined by using a Mumps-specific IgM Antibody Capture Radioimmunoassay (Perry et al. 1993).
2. Results 79
Figure 2.12 shows the distribution of GACELISA results in each age cohort. As 
expected, unvaccinated subjects in group 1 had very low log(T/N) values. Similarly, most 
of the unvaccinated subjects in group 2 had very low log (T/N) values, whereas in group 3, 
a wider spread of log(T/N) values was observed in those unvaccinated. Most likely some 
of the subjects in this cohort (8.99-19.99 years) had been exposed to natural mumps 
infection. In group 4, most of those unvaccinated had relatively high log(T/N) values due 
to natural mumps infection. The highest log(T/N) values were observed in those that were 
also IgM positive, most of which were in group 3 (teenagers). Most vaccinated subjects 
were in groups 2 and 3 and the distribution of results in these two age groups appeared very 
similar, despite many (56%) in group 2 having had received two doses of vaccine.
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clonal antibodies labelled with a chemiluminescent 
acridium ester was shown to be 50 photon counts per 
attomole of label (Weeks et al., 1984). Similarly, the 
use of europium labels in time-resolved fluorescence 
has permitted the development of sensitive immuno- 
assays by reducing background noise and conse- 
quently increasing signal-to-noise ratios (Jackson 
and Ekins, 1986).
Enzymes such as horseradish peroxidase and alka- 
line phosphatase have also been widely used as labels. 
They have the potential for signal amplification since 
one molecule of enzyme may catalyse the conversion 
of many substrate molecules to detectable product. In 
practice, however, the colorimetric substrates used to 
monitor enzyme activity limit the sensitivity with 
which enzyme labels can be detected since relatively 
large concentrations of chromogens need to be gen- 
erated for spectrophotometric detection. Enzyme as- 
says have therefore not usually demonstrated much 
greater sensitivity than radioisotopic methods, though 
the use of fluorogenic and radioactive substrates or 
enzyme amplification methods have increased detec- 
tion limits (Harris et al., 1979; Stanley et al., 1985; 
Johannsson et al., 1986; Ruan et al., 1993; Zhang et al., 
2001).
Recently, DNA labels that are detected using PCR 
have been used in the development of ultrasensitive 
immuno-PCR (iPCR) assays (Sano et al., 1992; Ru- 
zicka et al., 1993; Zhou et al., 1993; Hendrickson et 
al., 1995; Maia et al., 1995; Case et al., 1997; Wu et 
al., 2001). Sano et al. (1992) reasoned that since 
single target nucleic acid molecules can potentially 
be detected by PCR, the use of DNA labels would 
permit highly sensitive assays. Using this approach 
they were able to detect as few as 580 molecules of 
immobilised bovine serum albumin. To date, iPCR 
has been used for the sensitive detection of a variety 
of soluble protein molecules such as cytokines (Sanna 
et al., 1995; Saito et al., 1999), tumour markers 
(Suzuki et al., 1995) and hormones (Hendrickson et 
al., 1995). However, it has so far not been applied to 
the detection of antibodies to human pathogens. In 
this study we describe the development of a quanti- 
tative iPCR assay and assess its potential for the 
detection of antibody to mumps virus. Although the 
incidence of mumps in the United Kingdom has fallen 
to low levels since the introduction of measles, 
mumps and rubella (MMR) vaccination, serological
surveillance remains important to provide early warn- 
ing of any accumulation of susceptible individuals 
that could facilitate a resurgence of disease (Osborne 
et al., 2000).
2. Materials and methods
2.1. iPCR format
A schematic diagram of the iPCR assay developed 
for the detection of antibodies to mumps virus is 
shown in Fig. 1. First, serum samples were incubated 
in wells coated with recombinant mumps nucleopro- 
tein antigen. After washing, wells were incubated with 
a mixture of conjugate (anti-human IgG covalently 
coupled to capture oligonucleotide) and target DNA 
(tDNA), which was designed to hybridise to capture 
oligonucleotide. After washing, hybridised tDNA was 
released into solution by restriction enzyme digestion 
and subsequently quantified by real-time PCR using 
the LightCycler . The amount of tDNA released 
from the conjugate was proportional to the level of 
specific mumps IgG antibody in the test sample.
2.2. Design of target DNA, primers and probes
All oligonucleotides were synmesised by MWG- 
Biotech, UK (Milton Keynes, England) and are shown 
in Table 1. A single-stranded (ss) amplification target 
oligonucleotide (tDNA), 89 base pairs in length, was 
designed with six defined sequence regions: comple- 
mentary sequence to the capture oligonucleotide; 
Hind III restriction site; 5' primer sequence; comple- 
ment sequence to the 3' primer; and an internal probe 
sequence. Two primers (Table 1) of 20 base pairs in 
length were used to amplify a 67-bp region of the 
tDNA. They had a G+C content of 45-50%, similar 
melting temperatures and no complementary sequen- 
ces. Two additional oligonucleotides were used. The 
internal probe was designed to hybridise to a sequence 
between the primer sites and was used to detect 
specific PCR product during amplification. It was 
labelled with Cy5 at the 5' terminal and blocked with 
biotin at the 3' terminal to prevent it acting as a primer 
during PCR. The capture oligonucleotide was com- 
plementary to the 5' end of the tDNA and contained a 
Hind III restriction digest site to enable the release of
A. McKie et al. /Journal of Immunological Methods 261 (2002) 167-175
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Clostridium botulinum 
Antibodies in oral fluid
Novel methods for the detection of 
microbial antibodies in oral fluid
Anne McKie, Andrew Vyse, and Christopher Maple
Compared with blood, oral fluid has several 
advantages as a sample for antibody detection. It is 
simple, safe, painless, and cheap to collect. The only 
drawback is that while the antibody profiles indicate 
those in blood, they are at lower concentrations. 
Antibody capture assays are the method of choice for 
the detection of microbial antibodies in oral fluid, but 
their relative lack of sensitivity when based on 
conventional immunoassay techniques has mostly 
limited their use to epidemiological applications. 
Immuno-PCR and time-resolved fluorescence offer 
more sensitive detection systems that could be applied 
to oral fluid specimens. We review antibody detection 
in oral fluid and discuss immuno-PCR and time- 
resolved fluorescence as candidate systems. Both have 
the potential to broaden the applications of oral fluid 
testing to clinical diagnostics. 
Lancet Infectious Diseases 2002; 2: 18-24
18
Figure 1. Collection of oral fluid from an infant with an Oracol sponge swab.
Collection of oral fluid
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Antibodies in oral fl
Table 1. Mean immunoglobulin concentrations (mg/L) in plasma and 
salivary components.
Specimen
Plasma
Parotid saliva
Crevicular fluid
Whole saliva
igG
14730
0-36
3500
14-4
igM
1280
0-43
250
2-1
IgA*
2860
39-5
1110
19-4
"Although high concentrations of IgA are present in crevicular fluid, the diagnostic 
usefulness of this class of antibody is relatively limited compared to specific IgM and IgG. 
Sources: Brandtzaeg et al 1 and Roitt and Lehner'
Antibody-capture assay
Table 2. Characteristics of four oral fluid collection devices.
Collection
device
Salivette
OraSure
Omni-SAL
Oracol
Description
Chew cotton wool for 30 
to 45 s or place 
under tongue for 1 min 
Move pad gently along gum 
twice. Place against lower 
gum on one side and keep 
stationary for 2 min 
Place pad under tongue 
and keep until indicator of 
device turns blue 
Rub sponge firmly along the 
base of the gums (inside 
and out) of the upper and 
lower jaw, for 1 min, using an 
action similar to tooth brushing
Manufacturer Unit cost*
Sarstedt
OraSure 
technologies
Saliva Diagnostic 
Systems
Malvern Medical 
Developments
£0-36
£3-76
C2-20
CO-50
Figure 2. Four oral fluid collection devices. From left to right: Salivette, 
OraSure, OmniSAL, and Oracol.
*Unit costs at November 2001
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RIA Amplified ELISA
+TMB
125; 
Anti-mouse I 125 conjugate
Mouse mAB 
Antigen
Immunoglobulin (sample) 
Anti-human immunoglobulin
Mouse anti-FITC HRP 
conjugated mAB
mAB-FITC conjugate 
Antigen
Immunoglobulin (sample) 
Anti-human immunoglobulin
Figure 3. Radioimmunoassay (RIA) and amplified ELISA formats used in antibody capture assays for 
use with oral fluid samples. Immunoglobulin (IgG, IgM, or IgA) in the test sample is captured by 
immobilised anti-immunoglobulin. Specific antibody is then detected by the addition of an antigen, 
followed by either: mouse monoclonal antibody (mAB) and /'"-labelled anti-mouse immunoglobulin 
for the RIA; or fluorescein isothiocyanate (FITC)-labelled mAB, horseradish peroxidase (HRP)- 
labelled mouse anti-FITC mAB, and the chromogenic substrate tetramethylbenzidine hydrochloride 
(TMB) for the ELISA.
Immuno-PCR
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Pasteurella 
piscicida* 
Biotinylated DNA 
Streptavidin
Biotinylated antibody 
Antigen
Immunoglobulin (Sample) 
Anti-human immunoglobulin
PCR
Figure 4. Immuno-PCR using free streptavidin to link biotinylated DNA 
and detecting antibody. Immunoglobulin (IgG, IgM or IgA) in the test 
sample is captured by immobilised anti-immunoglobulin. Specific 
antibody is then detected by the sequential addition of an antigen, 
biotinylated antibody, strepatvidin, and biotinylated DNA. PCR is used to 
detect the DNA.
Time-resolved fluorescence (TRF)
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Fluorescence 
Excitation at 340nm
Search strategy and selection criteria
400
Time (M.S)
Figure 5. Measurement principle in time-resolved fluorescence 
The cycle time is 1ms and pulsed excitation less than 7jis occurs at the 
beginning of each cycle. The delay time after the pulsed excitation is 400 
us and the actual counting time within the cycle has the same duration. 
The total measurement time is 7s. Curve 1 represents the fluorescence of 
the europium chelate and curve 2 the background fluorescence (actual 
decay time less than 1\ts). Adapted from Lovgren and Hellstrand. 44
22
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